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PATHOLOGIC EFFECTS OF UREMIA IN THE KIDNEY AND BRAIN 
TERESA LYNN RUSSELL 
ABSTRACT 
 Chronic kidney disease (CKD), a reduction in kidney function, has reached 
pandemic proportions and imposes a major healthcare burden worldwide. A hallmark of 
CKD is the accumulation of several chemical compounds, called uremic toxins, which 
inflict systemic and renal-specific damage. Of the known uremic toxins, kynurenine 
(Kyn) is known to be particularly vasculotoxic and is implicated in several complications 
of CKD. Indoleamine 2,3-dioxygenase 1 (IDO), which catalyzes the first step in the 
metabolism of Tryptophan (Trp), regulates immune response to inflammatory cytokines 
in tissues. IDO plays a role in apoptosis and damage during acute kidney injury (AKI), a 
transient decrease in kidney function. During metabolism of Trp, IDO generates Kyn, a 
uremic solute, and therefore IDO may play a role in the brain and kidney damage due to 
accumulation of Kyn. The objective of the current study was to investigate the role and 
regulation of IDO in CKD pathology. Studies were performed to determine whether IDO 
is protective or pathologic and to find how IDO is regulated in the kidney during CKD. 
IDO in renopathology was examined using murine models of CKD. CKD was induced 
via a 0.2% adenine-supplemented diet (AD) model for 21 days. IDO regulation was 
examined using an Indoxyl Sulfate (IS)-specific solute model. Renal function in the 
IDO+/+ and IDO-/- AD mice was assessed through weekly measurement of blood urea 
nitrogen (BUN). H&E and Masson’s trichrome stains were used to assess percentages of 
glomerulosclerosis (GS) and immune infiltration (II), and combined interstitial fibrosis 
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and tubular atrophy (IFTA) score in IDO+/+ and IDO-/- mice with and without CKD. IDO 
protein concentration in the kidneys of all mice with and without CKD and IDO+/+ IS 
mice was determined via immunoblotting. Patients with kidney disease suffer from 
neuropsychological disorders and neurocognitive decline. The effects of uremic solutes 
on the CNS was examined using immortalized human umbilical endothelial vein cells 
(HUVEC-TERT), in vitro. Cell proliferation and viability, in the presence of IS, were 
measured by BrdU and Alamar blue assays, respectively. In both IDO+/+ and IDO-/-, 21 
days of AD results in significant deterioration of renal function. The average IFTA score 
and percentage of II in IDO-/- mice increased with AD compared to ND (p<0.05, 
p<0.001). IDO expression was seen sporadically in the glomeruli and walls of major 
vessels in the kidneys of 4d AD IDO+/+ mice, and in the tubules and vessel walls in the 
kidneys of 14d AD IDO+/+ mice. In IDO+/+ ND mice, endogenous IDO protein expression 
was undetectable at a signal intensity of 119.86 ± 268.01, whereas IDO+/+ AD mice 
showed a 370-fold higher level of IDO protein expression compared to IDO+/+ ND 
(p<0.001). IDO-/- AD IDO protein expression was 9.5-fold higher than in IDO-/- AD 
(p<0.05). IDO expression was found to be 58-fold higher in IDO+/+ mice with IS 
treatment (p<0.05). In the IS mice, non-significant trends toward decrease in cellular 
proliferation and viability with time were also observed (p=ns). IDO is upregulated at the 
protein level both in a CKD model and directly by the uremic solute, IS. IDO appears to 
be protective in the kidney during CKD, given the trend toward increased percentage of 
GS and II in IDO-/- compared to IDO+/+ mice with CKD, though there is little difference 
seen in total kidney IFTA. IDO upregulation is linked to increased apoptosis. Blocking 
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uremic solute production would therefore prevent IDO protein upregulation and reduce 
apoptosis, alleviating renal damage during CKD. 
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Kidney Structure and Function 
 The kidneys function to filter blood and secrete waste products through the 
urinary system. These paired organs of the genitourinary system sit retroperitoneally 
between the parietal peritoneum and the posterior abdominal wall on either side of the 
spine at the level of thoracic vertebra 12 - lumbar vertebra 3 1,2. They are highly 
vascularized, demanding about 20-25% of the body’s cardiac output, which is equal to or 
greater than that required by the brain (15-20%, though this may be modulated by factors 
such as age and body mass index (BMI))2,3. 
 The microscopic anatomy of the kidney is dominated by its functional unit, the 
nephron (Figure 1)4. Each human kidney contains approximately 1-2 million nephrons 
(with a range of around 200,000 to >2.5 million), each consisting of a renal corpuscle 
with an afferent and efferent arteriole and a series of tubules leading to a collecting 
duct1,2,5–7. Each afferent arteriole enters a specialized bed of glomerular capillaries where 
the blood is filtered and subsequently exits out the corresponding efferent arteriole. The 
renal corpuscle consists of a glomerulus surrounded by the Bowman’s capsule and 
filtering into the Bowman’s space2. Glomeruli have three specialized cell types: the 
fenestrated endothelial cells which surround each glomerular capillary, the mesangial 
cells, and the podocytes, specialized with foot processes creating filtration slits along the 






Figure 1: Microanatomy of a Nephron 
A nephron, the functional unit of the kidney, consists of a glomerulus, arterioles, and 
tubules. These nephrons number in the millions and are responsible for the many 
homeostatic systems kept in balance by the kidneys. A) A schematic of an individual 
glomerulus and its arterioles, showing its tubular connections is shown, otherwise known 
as a nephron or renal corpuscle. B) A medullary pyramid is shown, containing examples 
of cortical and juxtamedullary glomeruli with their many individual vascular and tubular 
connections. Reproduced from Encyclopedia Britannica, 2010.4 
 
 The main functions of the kidney include the balance of fluid, electrolytes 
(including sodium, calcium, phosphorus, and potassium), and acid-base, which contribute 
to osmotic, ionic, and pH homeostasis2,8,9. The kidneys also produce hormones to 
regulate renal and systemic blood pressure (via the renin-angiotensin-aldosterone system 
(RAAS)), erythropoiesis, and bone strength and health2,8,9. Lastly, the kidneys function to 
remove toxins and waste products from the body8. The tubules function to modify the 
filtrate into urine and proceed from the cortex into the medulla. Metabolic wastes are 
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drained out from the medullary ducts of Bellini into the calyces of each kidney and 
through the paired ureters for storage in the urinary bladder, which will ultimately drain 
out of the body through the urethra2. The maintenance of fluid volume and composition 
homeostatic function is achieved through filtration at the glomeruli followed by 
reabsorption of nutrients and excretion of waste productsw2. 
 The glomerular filtration rate (GFR) measures the total fluid filtration through all 
functioning nephrons per unit time and is the gold standard for estimation of renal 
function2,7,10. Glomeruli are able to temporarily increase their GFR to compensate for 
transient increases in filtration load without structural changes, but can be damaged by 
extended periods of compensation7. The GFR depends on the glomerular capillary wall 
permeability, systemic blood pressure, and effective filtration pressure2. A healthy GFR 
is defined as ≥ 90mL/min per 1.73m3, with the average normal GFR around 125mL/min 
per 1.73m3 2,10. Inulin is an inert, freely filtered, exogenous molecule that does not 
undergo tubular secretion or reabsorption and is not metabolized, so its rate of clearance 
is equal to the patient’s GFR2,10. An inulin clearance test, involving the intravenous 
injection and subsequent measurement of inulin, can be used to measure GFR2,10. Though 
it is the most accurate, the inulin clearance test rarely used in clinical practice due to its 
invasive, expensive, and time-consuming nature2,10. 
 In clinical practice, the GFR is estimated (eGFR) using creatinine clearance, 
measured by point-of-care testing using a small blood sample and/or through a urine 
sample, a vastly simpler and less expensive method2,10,11. Creatinine is an endogenous 
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compound produced during muscle metabolism, which is freely filtered by the 
glomerulus and is normally produced and excreted constantly at equal rates2,10,11. Levels 
of creatinine will increase as GFR decreases7,10. Creatinine also increases as muscle mass 
increases, necessitating standardized equations to find eGFR controlling for natural 
variabilities in muscle mass, including those due to sex, age, race, body surface area and 
BMI, such as the Modification of Diet in Renal Disease (MDRD) and CKD-
Epidemiology Collaboration (CKD-EPI)7,10–14. A healthy normal plasma creatinine value 
is between 0.7-1.5mg/100mL2. 
 Cystatin C, a protein produced by all cells, can also be measured to estimate 
kidney function, since its levels are regulated in the kidneys15. Although cystatin C varies 
less due to factors like muscle mass and diet, it is influenced by age, sex, inflammation, 
obesity, diabetes, corticosteroid use, smoking, and hyperthyroidism, making it less 
reliable as an individual biomarker7,10,11,13,15. It is therefore most often combined with the 
creatinine value in the CKD-EPI creatinine-cystatin C equation to provide a more 
accurate measure of eGFR, especially in the lower ranges7,10,11,13,15. This combined 
equation can help to control for skewed eGFR results due to high or low muscle mass, 
limb amputation, high protein diet, use of creatinine or protein supplements, or use of 
drugs which affect tubular creatinine secretion7,10,11,15. A healthy normal cystatin C value 
is 0.51-1.21 mg/L and will vary depending on the patient’s age and sex16. 
 Blood Urea Nitrogen (BUN) level, which rises as GFR decreases, can also be 
measured to assess renal function2,7. Since urea nitrogen is normally reabsorbed by the 
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tubules, its concentration in the blood reflects an individual’s capacity for glomerular 
filtration and urine concentration and will increase when the passage of fluid through the 
tubule slows (as in decreased GFR or dehydration)2. A healthy normal BUN is between 
5-21mg/dL or 1.8-7.1mmol urea/L2,17–19. This measure is a slightly less reliable indicator 
of renal function, as it can be affected by dietary protein intake, endogenous protein 
catabolism, hydration status, hepatic urea synthesis, and renal urea excretion2,19. To 
normalize BUN to a specific person, the BUN-to-creatinine ratio (BCR) can be used, 
which should fall between 6 and 25 in a healthy, normal individual18. 
 Proteinuria, another manifestation of renal dysfunction, is caused by an increase 
in the permeability of the glomerular capillaries to protein or a decrease in the tubular 
reabsorption of proteins in glomerular filtrate7,11,20,21. Since proteins should normally be 
largely or completely restricted from filtration by the glomeruli, proteinuria is an 
important measure of glomerular injury7,20,22–24. Due to the large molecular weight of 
albumin, albuminuria is an especially useful metric to assess the health of the filtration 
barriers7,20,22–24. Levels of proteinuria can be measured by 24-hour (24h) urine collections 
(reference standard) to get protein excretion rate (PER) or by spot urine sampling to yield 
protein-to-creatinine ratio (UPCR)7,10,20,23,24. A normal adult PER is less than 
150mg/m2/day, with PERs in children or infants tending higher, up to more than double 
the adult value10,23,24. A normal UPCR is less than 0.2, which is equivalent to 0.2g/day of 
protein excretion, in adults and less than 0.3 in children and adolescents and less than 0.5 
in infants and younger children20,24. Spot UPCR can also be used to determine the daily 
PER based on age, weight, and sex of the patient24. Levels of proteinuria or albuminuria 
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specifically can be measured by urine dipstick, which is sensitive to albumin 
concentration and gives a colorimetric measure of proteinuria of negative (< 10 mg/dL), 
trace (10-20 mg/dL), 1+ (30 mg/dL), 2+ (100 mg/dL), 3+ (300 mg/dL), or 4+ (1000 
mg/dL)10,20,23,24. Albuminuria can also be measured by 24h urine collections or 
microscopic analysis, albumin-to-creatinine ratio (ACR), urine electrophoresis, specific 
protein testing, and other assays7,10,11,22,23. Urine ACR is considered more standardized 
and precise than UPCR measurements and allows staging of albuminuria into categories 
A1 (< 30 mg/g), A2 (30-300 mg/g), and A3 (> 300 mg/g), with normal ACR value 
defined as < 30mg/g/day10,11,19,22,23. 
 Alterations in kidney function due to acute or chronic renal injury can be 
determined using the aforementioned methods. 
Chronic Kidney Disease 
Chronic Kidney Disease (CKD) is a major cause of morbidity and mortality in the 
US and internationally. Globally, an estimated 5-10 million deaths are attributable to 
CKD each year, a number which has increased over the past 20 years and is likely an 
underestimate due to a lack of awareness and access to diagnostic testing (Figure 2)25,26. 
According to the Center for Disease Control (CDC) and the National Institute of Diabetes 
and Digestive and Kidney Diseases (NIDDK), CKD in the United States (US) has 
increased over time to a recently stable 14-15% of adults (Figure 2)13,25,27–29. Up to 90% 





Figure 2. Global Chronic Kidney Disease Morbidity and Mortality 
A) Outlined in purple, the rise of CKD as a leading cause of DALYs worldwide between 
1990 and 2015 is shown. The percentage change in number of DALYs as well as all-age 
and age-standardized rates are shown. Statistically significant changes are bolded. B) 
Outlined in purple, the rate of change in CKD as a leading cause of DALYs stratified by 
age group. Red donates those symptoms with the highest rate of change (in the positive 
direction). Alzheimer’s = Alzheimer’s disease and other dementias, Back & neck = low 
back and neck pain, CKD = chronic kidney disease, Conduct = conduct disorder, 
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Congenital = congenital anomalies, COPD = chronic obstructive pulmonary disease, 
DALYs = disability-adjusted life-years, Depression = depressive disorders, Diarrhoea = 
diarrheal diseases, Drugs = drug use disorders, GBD = Global Burden of Disease, Haemog 
= hemoglobinopathies and hemolytic anemias, Haemol = hemolytic disease and other 
neonatal jaundice, HIV = Human Immunodeficiency Virus and/or Acquired Immune 
Deficiency Syndrome, HTN HD = hypertensive heart disease, IHD = ischemic heart 
disease, Intest inf = intestinal infectious diseases, Iron = iron deficient anemia, LRI = lower 
respiratory infections, Lung C = lung, bronchial, and tracheal cancers, MSK = other 
musculoskeletal disorders, NN Enceph = neonatal encephalopathy due to birth asphyxia 
and trauma, NN Preterm = neonatal preterm birth complications, NN Sepsis = neonatal 
sepsis and other neonatal infections, NN PEM = protein-energy malnutrition, Other NN = 
other neonatal disorders, Sense = sense organ diseases, Skin = skin and subcutaneous 
diseases, STD = sexually transmitted diseases excluding HIV, Stomach C = stomach 
cancer, Stroke = cerebrovascular disease, TB = tuberculosis, Violence = interpersonal 








CKD is classified according to GFR and albuminuria, which are combined to estimate 
progression risk, illustrated here by color from green to deep red. Green is stable disease, 
the least likely to progress, whereas deep red is the most severe disease, most likely to 
progress. Patients with CKD will need more careful and frequent monitoring as their risk 
of progression increases. CKD = chronic kidney disease, GFR = glomerular filtration rate 
Reproduced from KDIGO 2012 Clinical Practice Guidelines, 2012.30  
 
CKD is currently defined by the NIDDK as any condition causing a prolonged 
reduction in kidney function27. Internationally, CKD is described as decreased kidney 
function (defined as a GFR of ≤ 60mL/min per 1.73m3) and/or markers of kidney damage 
(including albuminuria, history of kidney transplantation, or abnormality in urinary 
sediment, macrostructure detected by imaging, microstructure detected on histology, or 
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electrolytes, or other evidence of tubular disorder) for at least 3 months regardless of 
etiology7,10,11,14,29,30. CKD is further subcategorized according to GFR and proteinuria, 
allowing for more precise prognostication of risks, such as cardiovascular mortality and 
end-stage renal disease (ESRD), based on disease severity and accounting for the two 
strongest risk factors for kidney failure (Table 1)7,11,21,29,30. UPCR and/or ACR, 
approximating glomerular filtration, can serve as an effective screening tool for CKD7,21. 
A UPCR > 0.2 or ACR ≥ 30mg/day signify renal disease10,11,20,22–24. An increased BUN 
or BCR can also be indicative of acute kidney injury (AKI) or CKD17–19. Patients often 
need to be reassessed to determine the duration of their kidney dysfunction, in order to 
distinguish AKI, a 2-7 day decrease in kidney function, or acute kidney disease (AKD), a 





Figure 3. Estimated Population-Based Prevalence of Chronic Kidney Disease 
Prevalence estimations of CKD based on populations of 7 major countries between 1995-
2208 are shown. The overall prevalence values are broken down by CKD stage, with cases 
of stage 1 shown in purple, stage 2 in green, stage 3 in orange, and stage 4 in blue. Across 
all countries, CKD Stage 3 represented the highest percentage, with marked exception of 
China, where CKD stage 1 was the most prevalent. Reproduced from ACR = albumin-





Worldwide, CKD affects an estimated 8-16% of the population, a likely 
underestimate as it often goes undiagnosed7,11,29. Prevalence across Europe, Asia, North 
America, and Australia is estimated at 1.7-13.1%, depending on the definition of CKD 
used, but numbers in developing countries remain largely unknown7,21,29. CKD stage 3 is 
the most common globally, with prevalence measured at 3.5%, 3.9%, 7.6%, 0.4%, and 
0.1% for CKD stages 1-5, respectively (Figure 3)13. The average rate of GFR decline in 
the general US population is approximately 1 mL/min/1.73m2/year, conferring a lifetime 
risk greater than 50% of developing GFR < 60 mL/min/1.73m2 11. CKD is most common 
in women, non-Hispanic African Americans, followed closely by those of any race 
identifying as Hispanic, and those over 65 years of age7,13,28,29. CKD rates are estimated 
up to 35% in those over 65 21. CKD also imposes a large financial burden, amassing 2-
3% of the annual health care spending on the < 0.03% of the population in high-income 





Figure 4: Interplay Between Chronic Kidney Disease and Cardiovascular Disease 
Risk Factors 
 
The highest CKD mortality is related to CVD, as a result of many overlapping risk factors, 
shown here. Both classical and non-classical risk factors can cause or be caused by renal 
dysfunction. All these risk factors lead to vascular injuries, which in turn lead to renal 
dysfunctions. CKD = chronic kidney disease, CVD = cardiovascular disease, Ca-P 
abnormality = Calcium-Phosphate abnormality. Reproduced from Ito 2012.31 
 
According to the 2015 Global Burden of Disease (GBD) study, the global 
disability-adjusted life years (DALYs) (which combine the metrics of years lived with 
disability and those lost to premature mortality) due to CKD (directly) and due to 
conditions associated with CKD (indirectly), such as cardiovascular disease (CVD) 
(Figure 4), cancer, diabetes, and neurological conditions, increased significantly from 
1990-201525,26. The leading cause of CKD mortality is CVD, therefore CVD risk 
management is a main feature of CKD treatment (Figure 4)7,11,21,31,32. CKD can 
contribute to increased morbidity and mortality indirectly through exacerbation of CVD, 
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infectious and neurological diseases, hypertension, and diabetes, among other conditions 
(Figure 5)7,14,21,25,26,31,32.  
 
 
Figure 5: Risk Factors for Chronic Kidney Disease 
 
Clinical, sociodemographic, and genetic risk factors for CKD are shown. Having one or 
more of these risk factors can put an individual at a higher risk for developing CKD. HIV 
= human immunodeficiency virus, APOL1 = Apolipoprotein L1. Reproduced from Chen 
et al. 2019.11 
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The main causes of CKD in the US are high blood pressure and diabetes, with 
almost half of CKD patients also suffering from diabetes or CVD, but CKD can have a 
myriad of causes related to many different risk factors (Figure 5)11,21,27. In high- and 
middle- income countries, CKD is more often caused by chronic issues like hypertension, 
diabetes, increased BMI, smoking, and history of CVD (Figure 5)7,11,13,21. Whereas CKD 
in low- and middle- income countries is most often due to glomerulonephritis and 
infectious diseases such as human immunodeficiency virus (HIV), hepatitis B and C, and 
malaria, as well as environmental exposures to chemicals like lead, cadmium, and 
mercury (Figure 5)7,11,13,21. Other causes of CKD include malignancy, autoimmune 
disease, other nephrotoxic exposures, such as pesticides, air pollution, and herbal 
remedies, and genetic predisposition, such as through the sickle cell trait, uromodulin 
(UMOD) gene, and 2 apolipoprotein L1 (APOL1) risk alleles (Figure 5)7,11,13,32. Certain 
countries see CKD of unknown etiology, characterized by extensive interstitial fibrosis 
and tubular atrophy (IFTA) and rapid progression without proteinuria13. CKD is also 
often comorbid with infection, AKI, and physical and cognitive dysfunctioning21. Though 
the cause CKD can be difficult to pinpoint, most cases can be generally categorized by 
the presence or absence of systemic disease (such as malignancy, chronic infection, 
diabetes, or autoimmune or genetic disorders, where the kidney is not the only affected 
area, etc.) and anatomical location of the kidney dysfunction (such as glomerular, 




Clinical Diagnosis of CKD 
 Clinically, CKD is most often diagnosed incidentally, through abnormal values 
returned from routine diagnostics10,11. When symptomatic, common presenting signs and 
symptoms include proteinuria, hematuria, nocturia, decreased urine output, or flank pain 
in the early stages or fatigue, nausea, vomiting, decreased appetite, weight loss, metallic 
taste, pruritus, dyspnea, peripheral edema, shortness of breath, or altered mental status in 
more advanced stages (Figure 6)7,10,11. As CKD worsens and GFR decreases, so do 
symptoms of CVD, arteriosclerosis, microvascular disease, left ventricular hypertrophy, 
large-vessel coronary disease, and myocardial fibrosis and the probability of life-
threatening cardiac events31,32. CKD can lead to many complications, including CVD, 
hypertension, hyperuricemia, anemia, hypervolemia, metabolic acidosis, mineral bone 
disorder (characterized by vitamin deficiency, hyperparathyroidism, hyperphosphatemia, 
and hyperkalemia), dyslipidemia, endocrine disorders, and impaired growth in children7. 
These signs, symptoms, and complications occur with increasing kidney dysfunction, but 





Figure 6: Clinical Signs and Symptoms of Chronic Kidney Disease 
 
Common clinical signs and symptoms of CKD are shown, broken down into overarching 
categories and areas of disorder and also including possible causes of these observations in 
patients. Many other less common signs and symptoms are not shown, but several other 
manifestations in many different systems are possible. CKD = chronic kidney disease. 




 Pathologically, kidney diseases can be characterized by the affected renal 
compartment: glomerular, tubulointerstitial, or vascular33. Renal fibrosis is the common 
feature seen in CKD kidneys regardless of disease etiology (Figures 7 & 8b)7,10,33–35. 
This histopathology, characterized by glomerulosclerosis (GS), interstitial fibrosis (IF), 
and tubular atrophy (TA), is usually due to initiation of a pro-fibrotic myofibroblast 
phenotype in different renal cell types (Figures 7 & 8)7,10,33,35. Other common features 
include vascular injury and loss, often due to pericyte damage, increased hypoxia and 
ischemia due to marked fibrosis, and chronic immune infiltration (II) (Figure 7 & 8)7,33–
35. Glomerular injury leads to impaired filtration precipitating proteinuria and 
hypertrophy of adjacent uninjured nephrons7,33. The resulting glomerular hyperfiltration 
and hypertension can lead to podocyte damage, focal segmental and global GS, 
tubulointerstitial fibrosis (TIF), TA, and progressive nephron loss7,33. Endothelial 
damage, smooth-muscle and mesangial cell proliferation, and podocyte destruction at the 
GBM lead to GS progression7,10,33. Albuminuria, II, and injury to the tubular epithelial 
cells, especially in the proximal tubule, can lead to the release of pro-fibrotic and pro-
inflammatory cytokines and reactive oxygen species (ROS), promoting increased IF, TA, 
inflammation, and apoptosis7,10,33. Histological exacerbation of IF, TA, and scarring are 
correlated with increases in proteinuria and decreases in GFR10. Vascular injury can 
manifest as increased permeability of kidney microvasculature, leading to hypoxia, 






Figure 7: Clinical Histopathology of Chronic Kidney Disease 
 
Common clinical histopathological features of CKD are shown. A) Perihilar FSGS lesion 
in an enlarged glomerulus stained with PAS at 400X magnification. B) TA, II, and 
glomerulus with thickening and connective tissue infiltration in the GBM, Bowman 
capsule, and Bowman space in CKD stage 3b stained with PAS at 200X magnification. C) 
Extensive IFTA, inflammatory II, and enlarged glomerulus with GS stained with PAS at 
200X magnification. D) Area of scarring with IFTA, GS stained with SM at 100X 
magnification. E) Scarring with IFTA and GS stained with SM at 100X magnification. F) 
Artery with marked intimal thickening stained with SM at 100X magnification. G) Mild to 
moderate IF with enlarged glomerulus in CKD stage 2 stained with Masson’s Trichrome 
at 200X magnification. H) Tubules with hydropic vacuolation stained with Masson’s 
Trichrome at 400X magnification. CKD = chronic kidney disease, FSGS = focal segmental 
GS, GS = glomerulosclerosis, IFTA = interstitial fibrosis and tubular atrophy, II = immune 
infiltration, PAS = Periodic Acid-Schiff, SM = silver methenamine. Reproduced from 






Figure 8: Mechanisms of Kidney Injury in Chronic Kidney Disease 
 
A) The mechanism of glomerular hypertrophy and hyperfiltration following nephron injury 
is shown. Individual glomerular blood pressure (GBP) increases through activation of the 
RA[A]S when nephrons are injured, or the total number of nephrons is decreased. To 
compensate for this increased GBP and to maintain glomerular filtration rate (GFR), 
individual nephrons and their podocytes will hypertrophy through the action of TGFα and 
EGFR. As nephrons grow, podocytes will reach their hypertrophic limit, leading to 
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filtration barrier dysfunction and subsequent proteinuria. Continued stress on podocytes in 
advanced CKD leads to podocyte detachment and loss, while the CKD milieu in turn 
prevents their regeneration from PECs, leading to FSGS. B) The sequence of events leading 
to interstitial fibrosis is shown. As described in (A), nephron hypertrophy and subsequent 
glomerular hyperfiltration and proteinuria will increase as CKD advances. As nephrons are 
exposed to an increased load of proteins along with infiltrating immune cells, the tubular 
cells secrete pro-inflammatory cytokines, leading to inflammation and subsequent 
glomerulosclerosis, tubular atrophy, and interstitial fibrosis. Increased glomerular and 
tubular injury will feed into an injurious cycle further increasing nephron hypertrophy and 
therefore CKD symptoms. CKD = chronic kidney disease, RAS = renin-angiotensin 
[aldosterone] system, Na+ = sodium, PEC = parietal endothelial cell, TGFα = transforming 
growth factor-α, EGFR = epidermal growth factor, FSGS = focal segmental 
glomerulosclerosis. Reproduced from Romagnani et al. 2017.7  
 
AKI is a reversible form of kidney injury that is caused by ischemia and 
subsequent reperfusion of the kidney. AKI is characterized by reduced oxygen delivery to 
the kidneys, vascular injury, decreased nitric oxide (NO) generation, and platelet and 
leukocyte recruitment34. Hypoxia induced in AKI can worsen in CKD and, coupled with 
increased RAAS activation and decreased glomeruli count, can lead to increasingly 
imbalanced renal oxygen homeostasis34. Pericyte malfunction or loss, inflammation, and 
hypoxia can lead to micro and macrovascular injury, increasing vascular permeability 
causing tissue swelling, hindering renal perfusion leading to further hypoxia or necrosis, 
impairing vasoreactivity and coagulation leading to blood pressure and clotting issues, 




Animal Models of CKD 
 Many surgical and genetic models exist to reproduce structural and functional 
changes due to human chronic kidney disease in animal models, including Anti-GBM 
nephritis, 5/6 Nephrectomy, unilateral ureteral obstruction (UUO), deoxycorticosterone 
acetate (DOCA)-salt, and adenine-supplemented diet (AD) models (Table 2)37. The AD 
model is a non-surgical and non-genetic alternative, which is highly effective at 
producing CKD symptoms that mimic those seen in humans38,39. Creatinine, BUN, 
proteinuria, apoptosis, IF, and TA are also increased in the AD model as seen in humans 
with CKD (Figure 9)38–40. The AD model also leads to decreased amino acids, 
hypercalcemia, hyperalbuminemia, and increased vascular calcification and 
hyperlipidemia, changes which are sometimes seen in humans38–40.  
Variable effects of the adenine diet have been seen, depending on the species, 
percentage of adenine-supplement, and duration of diet administration39,40. In rats, a 
0.75% AD led not only to rapid-onset kidney damage but also marked body weight loss 
and mortality within 2-4 days of treatment, issues which are abated when the 
concentration is lowered to a 0.25%39,40. The 0.25% AD for 4-16 weeks in rats has been 
validated for use in induction of CKD in rats with an optimal level of kidney damage as 
well as other symptoms, including cardiac and bone pathology39,40. Doses of 0.2% for 4 
weeks, 0.25% for 10 days or 4 weeks, and 0.5% of AD for 3 weeks have all been 




Though the AD model has been found more sensitive in rats than mice, in both 
species it produces grossly hypertrophic kidneys that histologically feature 
tubulointerstitial crystal formation, interstitial II, IF, TA, GS, dilation and obstruction of 
tubular lumina, glomerular and tubular epithelial hypertrophy, erosion of proximal 
tubular brush borders, podocyte injury, overall appearance of oxidative stress, and the 
degeneration, necrosis, and flattening of proximal and distal tubular epithelia in both 
species (Figure 9)38–40. The crystalline deposits seen in this model are 2,8-
dihydroxyadenine, a metabolite of adenine which is poorly soluble in the tubules38,39. The 










Multiple murine models of CKD pathologies of varying etiologies are shown. Common 
pathological features of CKD can be produced by many surgical and genetic 
perturbations, with variable translational capacity to human diseases, as detailed here. 
Etiology or mechanism as well as translational capability to human models are included. 
Models are categorized by the CKD-related pathology which is their main feature. LN = 
lupus nephritis, GBM = glomerular basement membrane, Nep25 = nephrin-hCD25, DT = 
diphtheria toxin, PAN = puromycin aminonucleoside, MCD = minimal change disease, 
FSGS = focal segmental glomerulosclerosis, Nx = nephrectomy, HIVAN = human 
immunodeficiency virus-associated nephropathy, UUO = unilateral ureteral obstruction, 
CyA = cyclosporine A, SHR = spontaneously hypertensive rat, DOCA = 










(A, C) Control kidney of ND mouse and rat. (B, D) Kidney phenotype of mouse and rat on 
0.2-0.75% modulated AD. (E,G) Control kidneys of rats fed normal diet in H&E and 
Trichrome. (F, H) Kidney phenotype of rats fed 0.25% AD in H&E and Trichrome. A 
marked difference in tubular and glomerular morphology is seen between each of the ND 
and AD images. In (A), the mouse glomeruli appear healthy and full, surrounded by a dense 
array of tubules, whereas in (B), the glomeruli appear degenerated, with an increase in size 
of the Bowman’s space, marked tubular dilation and likely atrophy, and immune 
infiltration shown by an increase in cellularity observed. Similar findings are shown in (C) 
and (D) in the rat kidneys, with the ND kidney showing a wider Bowman’s space and larger 
tubular lumina, but similarly dilated tubules and immune infiltration, with the addition of 
increased glomerular damage and hemorrhage. The ND rat kidneys in (E) appear similar 
to those in (C) with the different appearance due to stain and possibly location of the slice 
within the kidney. (F) shows the same pathological features as (D) with the addition of 
tubular crystalline deposits. (G) and (H) show an increase in fibrosis due to AD, seen as an 
increase in blue-stain in the Trichrome images. ND = normal diet, AD = adenine-
supplemented diet, H&E = hematoxylin and eosin, Trichrome = Masson’s trichrome. 
Modified from Ali et al. 2013 and Diwan et al. 2017.39,40  
 
Uremic Milieu in CKD 
A hallmark of CKD pathophysiology is the build-up and retention of uremic 
solutes or toxins which leads to adverse biological effects in the kidney and other organ 
systems10. These uremic solutes accumulate in circulation with impaired renal function 
and increase in concentration as CKD becomes more advanced42,43. These uremic solutes 
are correlated with increased mortality in CKD patients, especially from cardiovascular 
events44. Uremic toxins fall into three broad groups based on solubility, binding capacity, 
and molecular size: small (< 500 Dalton (Da)) water-soluble compounds (oxalate, urea, 
guanidines, and polyamines), small lipid-soluble or protein-bound compounds (indoxyl 
sulfate (IS), indoxyl acetate (IA), kynurenine (Kyn), p-cresyl sulfate (PCS), and 
homocysteine), and larger (> 500 Da) middle molecules (parathyroid hormone, beta β2 
microglobulin, and advanced glycosylated end products)10,43. While small water-soluble 
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compounds are easily removed by dialysis, small protein-bound compounds and larger 
middle molecules do not dialyze well43. Due to protein-binding and poor dialyzing, the 
small lipid-soluble molecules, mostly indoles and phenols, are likely to contribute to 
vascular complications in the setting of CKD10,43,45.  
Uremic solutes have been implicated in atherosclerosis and other vascular 
diseases often associated with CKD44. The uremic solutes have also been demonstrated as 
CKD-specific factors influencing nearly all components of thrombosis43,46. Accumulation 
of uremic solutes in CKD has been shown to lead to an increase in both venous and 
arterial thrombosis, through different pathways, seen in ex vivo models, mouse models, 
and human trials43,46. Due to high levels of these uremic solutes, neither conventional 
antiplatelet nor antithrombotic agents are effective in preventing thrombosis in patients 
with CKD43. Increasing levels of IS or Kyn correspond with higher CKD-induced 
thrombosis stages in mouse models, possibly using their known action of increasing 
tissue factor (TF) via the aryl hydrocarbon receptor (AHR), through the IS/Kyn-AHR-TF 
thrombosis axis43,46,47.  
Indolic solutes, such as IS, which is produced by tryptophan (Trp) metabolism, 
induce spontaneous venous thrombosis by increasing TF in both the endothelial cells 
(ECs), through increased AHR signaling, and vascular smooth muscle cells (VSMCs), 
through inhibition of ubiquitination and subsequent degradation of TF, surrounding the 
vasculature43,46,47. Both IS and IA are found in systemic circulation bound to albumin and 
are excreted in the kidneys by the tubular epithelial cells by the organic anion transporters 
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(OATs) 1 and 3 43. Both IS and PCS have been correlated to Fas levels, implicating them 
in Fas/FasL pathway induction44,48. Additionally, both IS and PCS have been associated 
with renal progression and mortality49.  
Kynurenines such as Kyn, kynurenic acid (KA), anthranilic acid (AA), Quinolinic 
acid (QA), and xanthurenic acid (XA) are also produced through Trp metabolism42,43. 
Kyn and Kyn metabolites have also been shown to accumulate in the plasma and tissues, 
including the kidney, in the setting CKD42,43. Kyn and KA levels have been correlated 
with eGFR and serum urea concentration measurements49. Increased Kyn has further 
been implicated in exacerbation of kidney damage through induction of enhancing 
pathological mitosis and apoptosis of kidney epithelial cells, impairing endothelial and 
epithelial cell functioning42. Kyn has also been associated with a hypercoagulable state 
and the TF-AHR pathway43,46,47.  
Abnormally increased Trp metabolism, leading to decreased Trp and increased 
Kyn and other metabolite concentrations in the plasma and tissues, has been observed in 
mouse, rat, and human CKD, proportional to the severity of renal impairment as well as 
BUN and serum Crt levels41,42. Decreased total serum Trp and increased or unchanged 
free Trp have been shown in patients with renal insufficiency41. Conversely, higher Trp 
concentrations were associated with decreased chance of progression to ESRD in patients 
with early stage CKD and excretion of Trp and KA were increased in diabetic patients 
with progressively increasing albuminuria49. These effects on Trp and Kyn metabolites in 
the setting of CKD may be due to induction of enzymes in the Trp metabolism pathway42. 
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Uremic solute concentrations are increased in later stages of CKD and have been 
implicated in the eGFR decline41,49. Uremic solutes have been shown to alter 
mitochondrial functioning, increasing superoxide and hydroxyl radical production, and 
inducing apoptosis and epithelial-to-mesenchymal transition in the proximal tubule 
cells49. These solutes also decrease the excretion of drugs, solutes, and waste products by 
inhibiting tubular transport proteins, competing for OATs and efflux pumps43,49. In 
studies of patients with different stages of CKD with rapidly declining eGFR, uremic 
solute concentrations were found to vary greatly over time and therefore the correlation 
between specific solute concentrations and eGFR decline requires further investigation49.  
Uremic solutes including Kyn, KA, QA, and XA have also been shown to 
accumulate in the central nervous system (CNS), plasma, and peripheral tissues42. Many 
Kyn metabolites are neuroactive and can lead to CNS diseases when dysregulated50. 
Disturbances in Trp levels have been associated with many disorders including 
depression, schizophrenia, and neurodegeneration50. Studies have demonstrated that QA 
is able to penetrate the blood-brain barrier (BBB), leading to agonistic effects on the N-
methyl-D-aspartate (NMDA) receptor, neuronal death through ROS generation, induction 
of lipid peroxidation in the brain, inhibition of cardiac contractility, and causing 
convulsions, seizures, and nerve cell death in large concentrations41,42. In contrast, KA 
has been shown to antagonize the NMDA receptor but may also induce convulsions at 
high levels41,42. Additionally, increased Trp and Kyn levels have been measured in the 
cerebrospinal fluid (CSF) and brains of rats and patients with CKD41. As renal function 
worsens, significant increases in the levels of Kyn and QA in serum and CSF, implicating 
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Figure 10: Uremic Solute Levels in Animal Model of Chronic Kidney Disease 
 
Levels of Kyn (A, C) and QA (B, D) are significantly increased in both serum (A, B) and 
CSF (C, D) with worsening levels of renal insufficiency in rats compared to controls 
(p<0.01). A surgical model leading to 2/3 (mild) or 5/6 (severe) nephrectomy was used to 
induce CKD and was compared to sham-operated control in rats. CKD = chronic kidney 
disease, QUIN = quinolinic acid (QA). Reproduced from Saito et al., 2000.41 
 
Indoleamine 2,3-dioxygenase 1 
 Indoleamine 2,3-dioxygenase 1 (IDO) is an intracellular, monomeric, ~45kD 
molecular weight protein containing two alpha helical domains separated by a heme 
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prosthetic group that is encoded by a gene on human and mouse chromosome 8 51–53. IDO 
is found in most tissues, including spleen, kidney, and brain and its expression can be 
constitutive or inducible depending on the organ51,52,54,55. IDO enzymatically catalyzes 
the conversion of L-Trp to N-formylkynurenine (NFK) by oxidative cleavage of the Trp 
indole ring 2,3-double bond, the initial and rate-limiting step of the Kyn pathways of Trp 
metabolism that can ultimately lead to production of nicotinamide adenine dinucleotide 
(NAD) and acetyl-coenzyme A (CoA) (Figure 11)45,51–56. Trp is the least abundant 
essential amino acid and active Kyn metabolites include Kyn, KA, QA, and IS45,49,51–54. 
IDO activity can be estimated using the ratio of Kyn/Trp present in an organism45.  
Two related enzymes, tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-
dioxygenase 2 (IDO2) also contribute to the Kyn pathway52,57. TDO is highly expressed 
in the liver, but is also found in a variety of other locations including the placenta, gravid 
uterus, maternal and embryonic tissues in early pregnancy, epididymis, testes, and 
brain52,55. TDO and IDO have similar enzymatic function, but both appear in most 
animals and some effects, such as dendritic cell (DC) Trp metabolism contributing to 
immune tolerance, are hypothesized to be uniquely attributable to IDO, suggesting 
different functional niches57. TDO is specific for L-Trp and select indole derivatives, 
whereas IDO reacts more broadly with related substrates (as does IDO2)52,54. IDO2 is 
constitutively expressed mainly in the kidney tubules, liver, epididymis, testes, 
spermatozoa, and antigen-presenting DCs52,54,55. IDO2 diverged from IDO more recently, 
sharing 43% homologous amino acid structure, and is encoded from a similar and 
biologically adjacent gene to that which encodes IDO54,55,57. Though IDO and IDO2 are 
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expressed in some of the same tissues, immunohistochemical studies have demonstrated 
their expression to be in distinct cell types within those overlapping tissues54,58. 
Compared to IDO, IDO2 has been shown to have far lower catalytic efficiency in the 
metabolism of Trp and does not have the same signaling capacity4252,54,55,57. While the 
function of IDO2 is still unclear, it seems to appear in similar locations as IDO, though its 







Figure 11: Kynurenine Pathway of Tryptophan Metabolism 
 
L-Trp is catabolized to Kyn by IDO in many tissues. Kyn is then further metabolized to 
several metabolites which can have further actions throughout the body. IDO = 
indoleamine 2,3-dioxygenase 1, Kyn = kynurenine, Trp = tryptophan, TTS = tryptophanyl-
transfer RNA (tRNA) synthetase. Reproduced from Yeung et al. 2015.53 
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Classical Function of IDO 
Activity of IDO is increased in several tissue and cell types in response to 
immune stimulation, making it important in immune responses such as infection, chronic 
inflammation, allergic reaction, autoimmunity, and renal injury41,45,51,53. Its upregulation 
in these settings is due to induction of the IDO gene at the transcriptional level in 
response to inflammatory stimuli51. IDO messenger RNA (mRNA) is stimulated most 
markedly by Interferon-γ (IFN-γ) and to a lesser extent by Tumor Necrosis Factor-α 
(TNF-α), Lipopolysaccharide (LPS), as well as other cytokines such as interleukins and 
other interferons51,52,56,57,59. IDO is inhibited by 1-methyl-DL-tryptophan (1-MT) and 
NO42,51,52,56,57,59. IFN-γ is an immune stimulatory cytokine that is produced by natural 
killer (NK) cells, CD4+ and CD8+ T cells, NK T cells, and other cytokines such as IL-12 
and IL-18 56. The function of IDO can differ depending upon which cytokines stimulate 
it. Its enzymatic activity is mainly driven by IFN-γ, leading to metabolism of Trp and 
production of Kyn metabolites56. Regulatory T cells use Kyn metabolites and cytokines 
to maintain an IDO-dependent regulatory environment, where IDO acts as a signaling 
molecule (Figure 12)56,60. 1-MT is a non-competitive inhibitor of IDO and may also 
interfere with transcellular Trp transport; it is being developed clinically to alleviate IDO-
mediated T cell suppression and possibly help increase the efficacy of certain cancer 
immunotherapy treatments60.  
IDO acts to deplete local Trp concentrations to regulate immune response and 
yield the various Kyn pathway metabolites which contribute to the aforementioned 
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uremic milieu51,53,56. Increased IDO activity has been observed in the setting of chronic 
infection, cancers, and neurological disease45. A balanced and controlled immune 
response is important as both too much (for example, leading to immune-mediated 
transplant rejection) or too little (leading to uncontrolled infections or cancers) can be 
damaging, dependent upon the situation51,53,56. The immunosuppressive effect of IDO 
aids in pregnancy, autoimmunity, and control of host response and the depletion of Trp 
inhibits the growth of many intra- and extra-cellular organisms50,51,53. However, the 
immunosuppressive actions of IDO can also be hijacked by certain cancers and pathogens 
to avoid immune response, allowing persistence of disease state in these cases50,51,53,56.  
IDO has been most extensively and classically studied in cancers. IDO has been 
implicated in induction of target genes as well as tolerance and immunosuppression, 
through the AHR pathway, activated by Kyn metabolites (Figure 12)47,60. IDO may also 
be involved in oncogenic tumor cell signaling and a regulatory phenotype in antigen 
presenting cells (APCs), possibly also through the AHR pathway, among other 
mechanisms (Figure 12)60. IDO likely works alongside other factors to aid in tumor 
immune invasion through the interactions of Kyn (and its metabolites) and the AHR in 






Figure 12: Tryptophan Metabolism in the Tumor Microenvironment 
Increased IDO and TDO expression by tumor and immune cells leads to a decrease in 
Trp and increase in Kyn and its metabolites. Kyn metabolites bind, causing the AHR to 
translocate to the nucleus, dimerize with AHRNT, bind DREs, and induce target gene 
expression. In tumor cells, IDO expression may be involved in signaling, such as Bin1 (a 
tumor suppressor gene) loss with activation of STAT1 and NFkB as well as STAT3 
activation via RTK mutations, such as KIT. In APCs, IDO may linked to a regulatory 
phenotype, driven in part by AHR activation, Treg cells (through PD-1/PD-L1 or 
B7/CTLA4), cell-cell contact with tumor cells, and soluble factors (i.e. PGE2, IFN, 
VEGF, and IL-10). Most between-cell transport Trp is via LATs (Trp/Kyn antiporters). 
APCs and tumor cells expressing IDO also have high-affinity Trp transporters, which 
direct Trp away from T cells (highly Trp dependent), inhibit CD8+ effector T cells, and 
increase Treg differentiation due to activation of GCN2 via buildup of unloaded tRNAs, 
mTOR signaling, and AHR activation. Tregs and tolerogenic APCs further inhibit 
immune response against tumor cells by releasing inhibitory cell surface proteins  and 
immunosuppressive cytokines. AHR = aryl hydrocarbon receptor, AHRNT = AHR 
nuclear translocator, APC = antigen presenting cell, CTLA = cytotoxic T-lymphocyte-
associated protein, DRE = digoxin response element, GCN = general control non-
derepressible, IDO = indoleamine 2,3-dioxygenase 1, IFN = interferon, IL = interleukin, 
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Kyn = kynurenine, LAT = light chain glycoprotein-associated amino acid transporter, 
mTOR = mammalian target of rapamycin, NFkB = nuclear factor kappa-light-chain-
enhancer of activated B cells, PD/PD-L = programmed cell death/programmed death 
ligand, PG = prostaglandin, RTK = receptor tyrosine kinase, STAT = signal transducer 
and activator of transcription, TDO = tryptophan 2,3-dioxygenase, tRNA = transfer 
ribonucleic acid, Treg = regulatory T cells, Trp = tryptophan, VEGF = vascular 
endothelial growth factor. Reproduced from Platten et al. 2015.60 
 
IDO in AKI and CKD 
The impact of IDO on renal diseases is still being elucidated. The role of IDO has 
previously been investigated in the setting of AKI59. IDO has been shown to increase in 
an ischemia-reperfusion injury (IRI) mouse model compared to sham-operated controls59. 
As increasing time elapsed after reperfusion, expression of both IDO mRNA and protein 
levels were markedly increased in IDO+/+ IRI mice kidney tissues, specifically shown in 
the tubular endothelial cells (ECs) of the renal cortex, compared to controls, where no 
deviation from baseline IDO expression was observed59. Additionally, in vitro ischemic 
conditioning models showed no such increase in IDO mRNA expression, suggesting a 
possible link to the reperfusion-associated inflammation59. In IDO-/- IRI mice, creatinine 
and BUN were significantly less than those in IDO+/+ IRI mice59. IDO+/+ IRI mice treated 
with 1-MT (a potent IDO inhibitor) also showed lower creatinine and BUN levels 
compared to IDO+/+ IRI mice without 1-MT59. Histological analysis of tubular damage 
showed decreased percentage of tubular necrosis and vacuolization as well as 
preservation of normal cellular architecture in the kidneys of IDO-/- IRI mice compared to 
IDO+/+ IRI mice59. Neutrophilic infiltration was higher in IDO+/+ IRI mice without 1-MT 
treatment compared to those administered 1-MT treatment59. Taken together, these results 
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give evidence for attenuation of IDO as a possible treatment for improving damage done 
by IRI and therefore potentially in renal transplantation59. IDO may also play a similar 
role in protection against chronic kidney disease, which the current study aims to 
investigate further59. 
Decreased Trp and increased Kyn metabolite levels (likely due to an increase in 
production and/or decrease in degradation) have been found in the blood and brains 
(particularly in the CSF) of animal models of CKD41,42,61. TDO activity in the liver has 
been shown to increase with increasing renal insufficiency, whereas IDO in most 
extrahepatic tissues showed no change, but did increase in certain tissues in relation to 
immune response41,42,61. IDO activity has been shown to increase with CKD severity, 
along with a concomitant increase in Kyn metabolites but Trp levels remained unchanged 
in the same animals45. Furthermore, though IDO activity correlated to measures of kidney 
function, changes in only some of the Kyn metabolites followed, and Trp did not45. IDO, 
Kyn, KA, and QA were found to be associated with key inflammatory markers, but Trp 
was not, which was suggested to indicate a primarily inflammatory mechanism to IDO 
induction in CKD45. Additionally, hemodialysis was found to have no effect on IDO 
activity and was only able to partially remove Kyn metabolites from patients’ systems, at 





 As previously mentioned, in the setting of CKD, uremic solutes have been 
implicated in increasing pathologic apoptosis, furthering damage seen in the 
kidneys42,48,49. Apoptosis is regulated, programmed cell death and can be both 
physiologically and pathologically (if there is too much or too little apoptosis) induced by 
a variety of stimuli48. Uremic serum has been demonstrated to augment apoptosis and 
certain uremic solutes have been correlated with levels of Fas, therefore accelerated 
apoptosis observed in patients with CKD has been hypothesized to be linked to the 
Fas/Fas ligand (FasL)-mediated pathway44,48. Uremic solutes have also been shown to 
increase AHR in kidney tissues and AHR signaling is involved in regulation of the Fas 
receptors and apoptosis, among other cellular processes47. 
The Fas/Fas FasL-mediated regulatory pathway can activate apoptosis of both 
glomerular and tubular cells as well as leukocytes48,62. Fas is a cell surface receptor 
expressed on leukocytes which interacts with membrane-bound or soluble FasL, a 
cytokine present in the cell membrane of mainly the proximal tubular ECs in normal 
kidneys (in vivo and in vitro)48,62. FasL is also expressed in the mesangial cells in the 
glomeruli and interstitium as well as leukocytes (especially activated) throughout the 
kidney, most robustly during injury48,62. An increase in tubular EC and total Fas/FasL has 
been observed in renal injury and inflammatory phenotypes in vivo and in vitro, which 
may lead to increased Fas/FasL-mediated apoptosis62,63. When directly treated with the 
inflammatory cytokines IFN-, LPS, and TNF- in vivo, both expression of Fas on the 
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surface of proximal tubular ECs and Fas/FasL-mediated apoptosis increased62,63. 
Additionally, protection from IRI-induced apoptosis has been observed in Fas-deficient 
tubular ECs62. 
 Since the activity of IDO is stimulated by the same pro-inflammatory cytokines, 
especially IFN-, and studies showing its expression in the tubular ECs therefore imply 
that it plays a role in Fas/FasL-mediated tubular EC apoptosis62,63. This activation of IDO 
and subsequent increase in tubular EC apoptosis has been demonstrated in vitro in 
primary renal proximal tubular ECs63. Additionally, in the same in vitro model, inhibition 
of IDO with 1-MT led to a marked decrease in tubular EC apoptosis63. Furthermore, these 
effects have also been demonstrated in vivo59. Kidney tubules of IDO+/+ IRI AKI model 
mice showed significantly more apoptotic cells (as measured by terminal 
deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling (TUNEL) 
assay) and Fas/FasL-mediated cell death than those of IDO-/- IRI or IDO+/+ 1-MT treated 
mice, suggesting that IDO plays a role in Fas/FasL-mediated apoptosis59. This has been 
examined in other cell types, where IDO in immune cells such as DCs and macrophages 
has also been shown to play a role in Fas/FasL-mediated apoptotic cell death as well as 






The purpose of this study was to investigate the role of IDO in renoprotection or 
renopathology in the setting of CKD and to elucidate the pathway through which IDO is 
regulated in the kidneys during CKD. 
 
Aim 1 
To characterize the effect of IDO on renal function in healthy and CKD mouse models. 
Aim 2 
To investigate the localization of IDO expression in kidneys and characterize the 
histopathological CKD phenotype. 
Aim 3 
To investigate the connection between IDO and apoptosis in kidney histology of CKD 
and uremic solute models. 
Aim 4 
To describe the effects of CKD and uremic solutes on IDO protein expression in mice. 
Aim 5 
To investigate the effect of uremic solutes on the central nervous system (CNS) 
vasculature in the setting of CKD. 
 
Hypothesis: IDO is upregulated in chronic kidney disease and contributes to the 






All animals were maintained in the Boston University (BU) Animal Care Facility 
(ACF), following Institutional Animal Care and Use Committee (IACUC) protocol 
number AN-15449.2016.03. Veterinary care and supervision were provided by the BU 
ACF staff. Animals were housed in individually vented cages with up to 3 males or 5 
females per cage. B6.129-IDO1tm1Aim/J (IDO-/-) mice were purchased from Jackson 
Laboratories (stock #005867) and bred in house (IDO-/-). C57BL/6J mice were purchased 
from Jackson Laboratories (stock #000664) (IDO+/+). 
 
Animal Model of Chronic Kidney Disease (AD model) 
Two groups of 10- to 12- week old mixed male and female IDO+/+ (n=4) and IDO-
/- (n=4) mice were subjected to a 0.2% adenine-supplemented diet (AD, Research Diets, 
#C17040502) for a total of 21 days (d) to induce CKD (Figure 13)38,64. This model of 
CKD is characterized by progressive tubular and interstitial crystalline deposits, 
increased fibrosis, decreased glomeruli count, Bowman’s capsule thickening, and luminal 
dilation (Figure 9)38. As the kidneys atrophy and body weight decreases due to the diet, 
urea nitrogen and creatinine levels increase in animals administered a 0.2% AD38,64. 
Another two groups of 10- to 12-week old IDO+/+ (n=5) and IDO-/- (n=4) mice were 
given a normal diet (ND) (Teklad Global 18% Protein Rodent Diet, Envigo) for 21d and 
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served as controls (Figure 13). In all AD mice, blood samples were collected 
longitudinally, on days 0, 7, 14, and 21 (0d, 7d, 14d, and 21d) (Figure 13). In ND mice, 
only terminal (21d) blood samples were collected (Figure 13). Blood samples were 
centrifuged at 2000 revolutions per minute (rpm) for 10 minutes (min) at 4C and the sera 
was transferred into corresponding 1.75mL tubes, flash frozen with liquid Nitrogen, and 
stored at -80C.  
All mice were sacrificed after 21d and standard necropsy was performed. After 
terminal blood samples were collected, tissues were perfused with excess cold 1X 
phosphate-buffered saline (PBS, 10X stock, pH 7.4, Boston Bioproducts, #BM-220), 
followed by harvest of the brain, aorta, and both kidneys. Sections of each brain and aorta 
and one kidney were flash frozen in liquid nitrogen, then stored at -80C. The rest of the 





Figure 13: Experimental Design of Adenine-Induced Model of Chronic Kidney 
Disease in Mice 
 
Four total mouse groups were used in this experiment, two IDO+/+ on ND or AD and two 
IDO-/- on ND or AD. Longitudinal blood samples were collected from each subject in the 
AD mouse groups at 0, 7, 14, and 21 days, and a single terminal blood sample was taken 
at 21 days for each mouse in the ND groups. IDO = indoleamine 2,3-dioxygenase 1  
 
Indoxyl Sulfate Solute-Specific Model of Uremia 
 A group of male and female 10- to 14- week old IDO+/+ mice (n=4) were 
administered IS at a concentration of 4mg/mL through drinking water, ad libitum. IS 
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excretion through OAT channels 1 and 3 was inhibited by twice daily administration of 
probenecid (15mg/kg, intraperitoneally (IP)), as previously described46,47,65. IS 
concentrations were measured at the end of the treatment protocol to assess IS levels in 
IS-specific solute model mice and ND control mice. All mice were sacrificed after 4d and 
standard necropsy was performed. Tissues were perfused with excess cold 1X PBS (10X 
stock, pH 7.4, Boston Bioproducts, #BM-220) followed by harvest of the brain, liver, and 
kidneys. Sections of each brain and aorta and one kidney were flash frozen in liquid 
nitrogen, then stored at -80C. The rest of the tissues were fixed in 1:10 formalin and 
processed according to a standard protocol. 
 
Histological Slide Preparation 
The formalin-fixed tissues were processed according to a standard protocol and 
were then embedded in paraffin wax blocks and effaced. The blocks were cut into 5µm 
sections and mounted on charged slides for histology and immunohistochemistry then 
baked at 80C for 1 hour (h).  
 
Histological Staining and Analysis 
Tissue slides were stained according to standard protocols to examine structural 
changes of the tissues in response to CKD conditions (AD). Slides were stained with 
Hematoxylin and Eosin (H&E) according to standard protocols to visualize the tissue 
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architecture. Fibrosis was assessed using Masson’s Trichrome and Picrosirius Red 
(Abcam, #ab150681) staining, according to standard protocols. Slides were analyzed 
using IFTA scoring performed by a blinded pathologist, as previously described66. IF and 
TA were both given a relative score from 1-4, with 1 signifying none of the morphology 
and 4 defined as presence of the morphology over the majority of the kidney being 
analyzed (Figure 14). These two scores were combined for each subject to yield a 
composite IFTA score of 2-8. The same blinded pathologist also analyzed the slides for 






Figure 14. Representative Histopathologic Images for Interstitial Fibrosis and 
Tubular Atrophy Scoring  
 
(A-C) Representative images of interstitial fibrosis scores 1-3 from sample mice, stained 
with Masson’s Trichrome, A=1, B=2, and C=3. None of the sample mice in this 
experiment were found to have an IF score of 4, therefore it is not shown. (D-G) 
Representative images of tubular atrophy scores 1-4 from sample mice, stained with 




Immunohistochemical staining for IDO was performed on formalin-fixed 
paraffin-embedded tissue sections. After deparaffinizing in xylenes and rehydrating in 
graded ethanols, antigen retrieval was performed by heating slides to 95C in 1X Sodium 
Citrate Buffer (100X stock, Vector Laboratories, H-3300) for 2 10 min cycles. All the 
following were performed in a humidified chamber at room temperature (RT) (unless 
otherwise indicated). The slides were then blocked with peroxidase (5 min), Avidin (15 
min), Biotin (15 min), and Horse Serum (15 min), with a 5 min 1X PBS (10X stock, pH 
7.4, Boston Bioproducts, #BM-220) wash in between each step (VECTASTAIN® Elite® 
ABC Universal Kit, Peroxidase (Horse Anti-Mouse/Rabbit IgG), Vector Laboratories, 
#PK-6200). Alternatively, slides were blocked with Hydrogen Peroxide (5 min) and 
Protein (30 min) Blocks with 2 5 min TBS-T (tris-buffered saline with Tween®: 1X TBS 
(10X stock, Boston BioProducts, #BM-301), 0.05% Tween® 20 (Sigma-Aldrich, 
Millipore Sigma, Merck, #P1379)) washes in between each step (Mouse and Rabbit 
Specific HRP/DAB IHC Detection Kit – Micro-polymer, Abcam, #ab236466). The slides 
were then incubated with an anti-IDO primary antibody overnight at 4C (Table3a). 
Then they were incubated with Biotinylated Secondary Antibody (30 min) and 
VECTASTAIN® Elite® ABC Reagent (30 min) with 2 5 min PBS (10X stock, pH 7.4, 
Boston Bioproducts, #BM-220) washes after each (VECTASTAIN® Elite® ABC 
Universal Kit, Peroxidase (Horse Anti-Mouse/Rabbit IgG), Vector Laboratories, #PK-
6200) (Table 3b). 3,3’-Diaminobenzidine (DAB) reagent was then added to one slide and  
the colorimetric reaction was monitored visually under the microscope (VECTASTAIN® 
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Elite® ABC Universal Kit, Peroxidase (Horse Anti-Mouse/Rabbit IgG), Vector 
Laboratories, #PK-6200). The reaction was stopped by incubating the slides in distilled 
water (diH2O). The remaining slides were incubated for the same time in DAB followed 
by diH2O. Slides were then dehydrated in graded ethanols, cleared in xylenes, and 
coverslipped with mounting medium (Vectamount™ Permanent Mounting Medium, 
Vector, #H-5000). The slides were digitally scanned using a Ventana Slide Scanner and 
its accompanying software. Higher magnification images were captured using the NIS-
Elements software on the Nikon TE 2000 Wide Field Immunohistochemistry Microscope 
in the BU Cellular Imaging Core Facility. Images were converted to RGB color in 
ImageJ (NIH, v1.52t). 
 










A) Primary antibodies used in all experiments are listed. B) Secondary antibodies used in 
all experiments are listed. IDO = indoleamine 2,3-dioxygenase 1, GAPDH = 
glyceraldehyde-3-phosphate dehydrogenase, MAb = monoclonal antibody, IgG = 
Immunoglobulin G, HRP = horseradish peroxidase 
 
Terminal Deoxynucleotidyl Transferase (TdT) Deoxyuridine Triphosphate (dUTP) 
Nick End Labeling (TUNEL) Assay 
Tissue slides were deparaffinized and rehydrated, followed by permeabilization in 
Proteinase K (1:100 Proteinase K: ddH2O, TUNEL Assay Kit Abcam #ab206386). After 
permeabilization, the positive control slide was incubated with DNAse I (1:10 DNAse I  
(Thermo Scientific, #EN0525): 1X TBS (10X stock, Boston BioProducts, #BM-301) + 
1mM magnesium sulfate (MgSO4, Fisher Scientific,  #M65)) and all other samples were 
incubated with 1X TBS (10X stock, Boston BioProducts, #BM-301) + 1mM MgSO4 
mixture (Fisher Scientific,  #M65), each for 20 min. Samples were then quenched for 5 
min with 30% hydrogen peroxide (H2O2) (1:10 30% H2O2 (Fisher Scientific, #S25360) : 
100% Methanol (Fisher Chemical, #H325)) and equilibrated for 30 min with TdT 
Equilibration Buffer (TUNEL Assay Kit, Abcam, #ab206386). Slides were labeled with 
the TdT enzyme (1:40 TdT Enzyme: TdT Labeling Reaction Mix, both TUNEL Assay 
Kit Abcam #ab206386) for 1.5h, then the reaction was terminated with Stop Buffer 
(TUNEL Assay Kit, Abcam, #ab206386). The slides were then blocked with Blocking 
Buffer (TUNEL Assay Kit, Abcam, #ab206386) for 10 min, detected with 1X Conjugate 
(1:25 25X Conjugate: Blocking Buffer, both TUNEL Assay Kit, Abcam, #ab206386) for 
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30 min, and developed with DAB (1:30 DAB Solution 1: DAB Solution 2, both TUNEL 
Assay Kit, Abcam, #ab206386) for 15 min. Finally, slides were counterstained with 
Methyl Green (TUNEL Assay Kit, Abcam, #ab206386) with 2 dips into a glass coplin jar 
(warmed to 60C). All steps from permeabilization to development were performed in 
humidified slide chambers at RT with a 5 min wash in 1X TBS (10X stock, Boston 
BioProducts, #BM-301) in between each step in plastic coplin jars. Slides were then 
dehydrated in graded ethanols, cleared in xylenes, coverslipped with mounting medium 
(Vectamount™ Permanent Mounting Medium, Vector, #H-5000), and left to dry in a 
fume hood overnight. The slides were scanned to digital using a Ventana Slide Scanner 
and its accompanying software. Higher magnification images were captured using the 
NIS-Elements software on the Nikon TE 2000 Wide Field Immunohistochemistry 
Microscope in the BU Cellular Imaging Core Facility. Positive cells, tubules, and 
glomeruli were then quantified by grid-counting with a cell-counter using ImageJ (NIH, 
v1.52t) of each scanned image at 20X magnification. 
 
Blood Urea Nitrogen Assay 
Frozen plasma samples were removed from -80C storage, thawed on ice, and 
vortexed. 5L of a blank (ddH2O), a standard (QuantiChrom™ Urea Assay Kit, 
BioAssay Systems, #DIUR-100), and each sample were added, in duplicate, to a 96-well 
culture plate. 200L of BUN Reagent (1:1 Reagent A: Reagent B, both QuantiChrom™ 
Urea Assay Kit, BioAssay Systems, #DIUR-100) was added to each well and incubated 
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for 20 min at RT. The optical density of each sample was then determined by measuring 
absorbance at 520nm using KCJunior (Bio-Tek, v1.3) and a 96-well plate reader. Using 
Microsoft Excel, the average, standard deviation, coefficient of variance, concentration of 
urea and BUN were calculated according to the guidelines of the kit. 
 
Tissue Lysis 
Flash frozen tissues were removed from -80C storage and placed into 
borosilicate glass tubes with tissue lysis buffer (Fisherbrand™, Fisher Scientific, #14-
961-27) (2% sodium dodecyl sulfate (SDS, Fisher Bioreagents, #BP166) 5mM 
ethylenediameinetetraacetic acid (EDTA, Sigma, #EDS), and 1mM Sodium 
Orthovanadate (Sigma, #S6308)). Samples were mechanically homogenized and 
sonicated to lyse the tissues. Cells were centrifuged at 14,000 rpm for 15 min at 4C to 
pellet insoluble debris. The supernatant was removed and kept. Protein concentrations 
were determined using Bicinchoninic Acid (BCA) Protein Lysate Assay (Pierce™ BCA 
Protein Assay Kit, Thermo Scientific, #23227) with absorbance measured at 562nm. 
Absorbances of the sample lysates were plotted against a standard curve to determine the 





Tissue lysates were mixed 4:1 with sample buffer (11.5:1 of stock buffer: -
mercaptoethanol (ME), 4X stock Boston BioProducts, #BP-110R) and denatured on a 
100C heat block for 7 min. Proteins were resolved using 10% SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) gels at 100V until the dye front reached the bottom of the 
gels. Proteins were transferred for 1h at 100V and 4C onto a nitrocellulose membrane 
(Bio-Rad, #1620112). Each nitrocellulose membrane was cut to separate the proteins of 
interest, and incubated with anti-IDO or anti-glyceraldehyde phosphate dehydrogenase 
(GAPDH) primary antibody (Table 3a) for 48h at 4C. After 3 10 min washes in TBS-T 
(1X TBS (10X stock, Boston BioProducts, #BM-301), 0.05% Tween® 20 (Sigma-
Aldrich, Millipore Sigma, Merck, #P1379), membranes were incubated in appropriate 
horseradish peroxidase (HRP)-conjugated secondary antibodies (goat anti-mouse or goat 
anti-rabbit HRP) for 1h at RT (Table 3b). The membranes were then washed again and 
developed using X-ray film (HyBlotCL®, Thomas Scientific, #1141J52) and HRP 
Substrate (Millipore, #WBLUC0500) at 1:4 or 1:1 concentration, depending on the 
protein band intensity. ImageJ was then used to quantify the band intensities for each 




Cell Viability Assay 
Immortalized human umbilical vein endothelial cells (HUVEC-TERT) were 
plated in 12-well cell culture plates at a density of 50-60% and allowed to adhere 
overnight at 37C in Dulbecco’s Modified Eagle Medium (DMEM, Corning, #10-017-
CV). Cells were then treated with increasing concentrations (0.1-100µM) of IS (Cayman 
Chemical, #16926), with dimethyl sulfoxide (DMSO, Sigma, #D8418)-treated cells (in 
the same concentrations) serving as controls. Cells were treated overnight at 37C. 
Following treatment, the media containing IS was aspirated and cells were washed twice 
with 1X PBS (10X stock, pH 7.4, Boston Bioproducts, #BM-220). Fresh media was 
added to each well and alamar blue (Bio-Rad, #BUF012A) was added so the final volume 
per well as 10% of the total volume. Fluorescence was measured at 585nm using a 
microplate reader at time (t) = 0, 15, 30, 60, 120, and 240 min post-alamar blue addition. 
Following the alamar blue assay, cells were washed twice in ice cold 1X PBS. Cells were 
lysed according to the plated cell lysis protocol and protein concentration was measured 
using Bradford protein assay, both detailed below. Fluorescence was normalized to the 
protein concentration per well. 
 
Cell Proliferation Assay 
 Immortalized HUVEC-TERT cells were plated at 50-60% confluence in a 96-well 
cell culture plate and allowed to adhere overnight at 37C in DMEM (Corning, #10-017-
CV). Cells were subsequently treated with 50µm IS (Cayman Chemical, #16926) 
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overnight. Proliferation was measured using Bromodeoxyuridine (BrdU) Cell 
Proliferation Assay (BrdU Cell Proliferation Assay kit, Millipore, #2750), following the 
manufacturer’s protocol. Briefly, following treatment with IS, cells were labeled with 
BrdU for either t = 0, 2, 4, 8, 12, or 16h. At the end of each time point, media was 
aspirated and cells were fixed with Fixing Solution (BrdU Cell Proliferation Assay kit, 
Millipore, #2750) for 30 min at RT. The Fixing Solution (BrdU Cell Proliferation Assay 
kit, Millipore, #2750) was aspirated off and wells were stored at 4C. After the 16h time 
point, all plates were thawed on ice and washed three times with 1X Wash Buffer (BrdU 
Cell Proliferation Assay kit, Millipore, #2750). Cells were incubated with an anti-BrdU 
antibody (BrdU Cell Proliferation Assay kit, Millipore, #2750) for 1h at RT to detect 
BrdU incorporation, then washed with 1X Wash Buffer (BrdU Cell Proliferation Assay 
kit, Millipore, #2750). Cells were subsequently incubated with a goat anti-mouse IgG 
peroxidase conjugate (BrdU Cell Proliferation Assay kit, Millipore, #2750) for 30 min at 
RT. After washing, the cells were incubated for 30 min at RT with TMB Peroxidase 
Substrate and the reaction was stopped using Stop Solution (both BrdU Cell Proliferation 
Assay kit, Millipore, #2750). Fluorescence was read at 450nm using a microplate reader. 
Fluorescence was normalized to protein concentration and shown as a relative 




Protein Concentration of Cultured Cells 
HUVEC-TERT cells in cell culture plates were placed on ice, washed with ice 
cold 1X PBS (10X stock, pH 7.4, Boston Bioproducts, BM-220), and lysed with 1X 
Radioimmunoprecipitation assay (RIPA) cell lysis buffer (100:1 of RIPA: 
phenylmethanesulfonyl fluoride, PMSF) (RIPA: 50mL RIPA stock buffer (Boston 
Bioproducts, #BP-115), supplemented with 0.02g Sodium Orthovanadate (Sigma, 
#S6308), 0.105g Sodium Fluoride (Sigma, #S7920), and 1 tablet of Pierce Protease 
Inhibitors (Thermo Fisher, #88265) and 1x PMSF: 139.36mg PMSF powder (Sigma, 
#P7626) in 10mL isopropanol (Fisher Bioreagents, #BP2618)) followed by collection of 
cells with a cell scraper into 1.75mL tubes. Cells were lysed by a rapid freeze/thaw cycle 
in liquid nitrogen and a 37C water bath. Cells were centrifuged at 14,000 rpm for 15 min 
at 4C to pellet insoluble debris. The supernatant was removed and kept. Protein 
concentrations were determined using Bradford Protein Assay (5X stock, Bio-rad Protein 
Assay Dye Reagent Concentrate, Bio-Rad, #5000006) with absorbance measured at 
595nm. Absorbances of the sample lysates were plotted against a standard curve to 
determine the concentration of each sample. 
 
Data Analysis 
Data were analyzed and graphs were created using ImageJ (NIH, 1997), Excel 
(Microsoft, 2020), and Prism 8 (Graphpad Software, 2018). Two-sided, unpaired 
Student’s T-tests with Welch’s corrections for unequal SDs were run to assess differences 
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between two groups. One-way Brown-Forsythe and Welch analysis of variance 
(ANOVA) tests (for unequal SDs) with Dunnett T3 correction for multiple comparisons 
(recommended for n<50/groups) were run to assess matched or repeated measures data. 
Mixed-effects analysis with Geisser-Greenhouse correction for sphericity and Tukey 
multiple comparisons tests for post-hoc t-tests were used for analysis of matched or 
repeated measures data with missing values (due to slightly different sample group sizes). 
Two-way ANOVA tests with Geisser-Greenhouse correction for sphericity and 
Bonferroni correction for multiple comparisons were run to assess the differences 
between multiple groups or time points. Tukey post-hoc t-tests were used to compare 
groups for ANOVA studies. Significance was set at an alpha of 95%, p = 0.05 (*). 
Further significance was benchmarked at p = 0.01 (**) for very significant, p = 0.001 
(***) for highly significant, and p=0001 (****) for the highest significance. Graphs 






Assessment of Clinical CKD Phenotype 
BUN was used to assess kidney function in both IDO+/+ and IDO-/- longitudinally 
in CKD mice to determine the effects of IDO on kidney function. The effect of AD on 
renal function was assessed in both IDO+/+ and IDO-/- mice through weekly plasma BUN 
testing of mice receiving the 0.2% AD, compared with a single point terminal plasma 
BUN level in mice receiving the ND (Figure 15). 
A mixed-effects analysis between all AD BUN time points (0d, 7d, 14d, 21d) in 
IDO+/+ mice showed a significant effect of diet duration (p=0.0004) (Figure 15a). The 
average BUN increased 140% from 0d to 7d, 193% from 0d to 14d, and 163% from 0d to 
21d (Figure 15a). The average BUN at 0d AD in IDO+/+ mice was 20.99 ± 1.33 
compared to an average BUN of 50.29 ± 11.35 at 7d AD, a non-significant trend toward 
increase (p=0.0537) (Figure 15a). Compared to the 0d AD average, the average BUNs of 
61.40 ± 4.03 at 14d and 55.43 ± 3.95 at 21d in the IDO+/+ were significantly increased 
(p=0.0017 and p=0.0016, respectively) (Figure 15a).  
A mixed-effects analysis between AD BUN time points (0d, 7d, 14d, 21d) in IDO-
/- mice also showed a significant effect of diet duration (p=0.0066) (Figure 15b). The 
average BUN increased 112% from 0d to 7d, 139% from 0d to 14d, and 106% from 0d to 
21d (Figure 15b). The average BUN at 0d AD in IDO-/- mice was 27.04 ± 8.38 compared 
to average BUNs of 57.46 ± 1.72 at 7d AD and 55.83 ± 2.30 at 21d, both non-significant 
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trends toward increase (p=0.0756 and p=0.0887, respectively) (Figure 15b). Compared 
to the 0d AD average, the average BUN in the IDO-/- mice was significantly increased at 
14d AD to 64.65 ± 1.79 (p=0.0482) (Figure 15b). Additionally, significant differences 
were observed between 7d AD and 14d AD BUN values (p=0.0006) and between 14d 
AD and 21d AD BUN values (p=0.0239) in the IDO-/- mice (Figure 15b). 
A two-way ANOVA performed between all diet groups (ND, 0d AD, 7d AD, 14d 
AD, 21d AD) within the IDO+/+ and IDO-/- genotype groups showed a highly significant 
effect of AD duration on BUN (p<0.0001) (Figure 15c). A Bonferroni’s multiple 
comparisons test revealed no significant difference between the IDO+/+ and IDO-/- 
genotype groups at any time point (p=ns) (Figure 15c). The average BUN of ND and 0d 
AD in both IDO+/+ and IDO-/- mice were similar, with BUN of 28.53 ± 4.97 for IDO+/+ 
ND and 25.55 ± 3.13 for IDO-/- ND and 20.99 ± 1.33 for IDO+/+ 0d AD and 27.04 ± 8.38 
for IDO-/- 0d AD (Figure 15c). The Bonferroni’s multiple comparisons test found no 






Figure 15: Blood Urea Nitrogen is Increased in Mice with Adenine-Induced Model 
of Chronic Kidney Disease 
 
A) The BUN of IDO+/+ mice was measured longitudinally at 0d, 7d, 14d, and 21d and 
values were compared by mixed-effects analysis. Significantly higher BUN was found at 
the 14d and 21d time points compared to 0d AD in these IDO+/+ mice (both p<0.001) and 
the increase at 7d approached significance compared to 0d. B) The BUN of IDO-/- mice 
was also measured longitudinally at 0d, 7d, 14d, and 21d and values were compared by 
mixed-effects analysis. Significantly higher BUN was found only at the 14d time point 
compared to 0d AD in the IDO-/- mice (p<0.05) and the increases at 7d and 21d approached 
significance compared to 0d AD. The 14d BUN was significantly higher than both the 7d 
and 21d BUNs (p<0.0001 and p<0.05). C) All sampled BUN values were compared 
between IDO+/+ and IDO-/- mice, and no difference was found between the two genotype 
groups at any time point (p=ns). Red horizontal lines represent the normal diet BUN level. 




Immunohistochemical Characterization of IDO Expression 
In order to characterize the localization of IDO expression in kidney tissues, 
archived tissues were stained immunohistochemically. Intestinal villi, with immune-cell 
rich lamina propria, where IDO is known to be expressed, served as positive and also 
negative (no-primary) controls. Sporadic but strong IDO expression was seen in the 
kidney tissues of IDO+/+ mice on AD for 4d, predominantly in localized to the glomeruli 
(Figures 16c, 16e, and 16f) and the vessel walls (Figure 16c). IDO was again 
sporadically but strongly expressed in the kidney tissues of IDO+/+ mice on AD for 14d, 







Figure 16: Subcellular Localization of Indoleamine 2,3-Dioxygenase 1 in IDO+/+ 
Mice with Adenine-Supplemented Diet Model of Chronic Kidney 
 
A) Negative (no primary) control B) Positive control of immune cells in the intestinal 
lamina propria (C-F) Glomerular and vessel wall expression of IDO in 4d AD IDO+/+ 
mouse kidney (G-J) Tubular and vessel wall expression of IDO in 14d AD IDO+/+ mouse 
kidney. All slides are imaged at 20x magnification. IDO = indoleamine 2,3-dioxygenase 
1, AD = 0.25% adenine-supplemented diet 
 
Characterization of Histopathological CKD Phenotype 
To assess the extent of kidney injury due to the CKD model, the H&E-stained 
tissue slides were evaluated for TA, GS, and II (Table 4 and Figures 18 and 19) and the 
trichrome-stained slides were evaluated for IF (with the IF and TA scores subsequently 
used to calculate IFTA scores as described above (Figure 13)) (Table 4 and Figure 17).  
A two-way ANOVA of the IFTA scores found that while there is no significant 
effect of the interaction between group and score (p=ns), the main effects of score and 
individual subject were highly significant (p<0.0001 and p=0.006, respectively) and the 
main effect of group approached significance (p=0.0781) (Table 4 and Figure 17).  
A Bonferroni’s multiple comparisons test revealed no significant difference 
between any of the groups for IF or TA individually (p=ns for all) (Table 4). The average 
IF scores for both ND groups were found to be comparable, 1.2 ± 0.447 for IDO+/+ ND 
and 1 ± 0 for IDO-/- ND (both out of 4), and the average IF scores for both IDO+/+ and 
IDO-/- AD groups were exactly the same, but the IDO-/- group had a nearly two-fold 
higher standard deviation (IDO+/+ AD: 1.75 ± 0.5, IDO-/- AD: 1.75 ± 0.957) (Table 4). 
The average TA scores for the groups were also similar, with a score of 1.4 ± 0.548 for 
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IDO+/+ ND compared to 1.75 ± 0.957 for IDO-/- ND and a score of 2.25 ± 1.5 compared 
to 2.75 ± 0.5 for IDO+/+ and IDO-/- AD, respectively (Table 4).  
When added, these scores yield average IFTAs that are similar within the ND and 
AD groups (Figure 17). IFTA was 54% higher in IDO+/+ AD compared to IDO+/+ ND 
mice (Figure 17a). The average IFTA for IDO+/+ ND mice was 2.6 ± 0.894, which was 
not found to be significantly different from that of IDO+/+ AD mice at 4 ± 1.414 (p=ns) 
(Figure 17a). IFTA was 64% higher in IDO-/- AD mice than in IDO-/- ND mice (Figure 
17b). In the IDO-/- mice, the average IFTA score of the AD group was significantly 
higher at 4.5 ± 1.291 compared to that of the ND group at 2.75 ± 0.957 (p=0.0359) 
(Figure 17b). A comparison of the AD mice of IDO+/+ and IDO-/- genotypes showed that 
IFTA increased by 12.5% between IDO+/+ AD and IDO-/- AD mice, a non-significant 
change (p=ns) (Figure 17c). 
A Brown-Forsythe and Welch ANOVA test on the GS data for all groups found 
no significant effect of group (genotype and diet) on the percentage of GS (p=ns) (Figure 
18). A Dunnett’s T3 multiple comparisons test confirmed this result, finding no 
significant difference in percentage of GS between any of the groups (all p=ns) (Figure 
18). The average percentage of GS was 4% ± 9% for IDO+/+ ND compared to 9% ± 12% 
for IDO+/+ AD, a non-significant 119% increase (p=ns) (Figure 18a). In IDO-/- mice, the 
average percentage of GS increased non-significantly by 114% between ND at 18% ± 
24% and AD at 38% ± 32% (p=ns) (Figure 18b). The average GS percentage was 329% 
higher in IDO-/- AD mice compared to IDO+/+ AD mice, a nonsignificant difference 
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(p=ns) (Figure 18c). 
An ordinary one-way ANOVA revealed a significant effect of group (genotype 
and diet) on the percentage of II (p=0.0003) (Figure 19). The average II percentages of 
each group were 2% ± 4% for IDO+/+ ND, 11% ± 5% for IDO+/+ AD, 0% ± 0% for IDO-/- 
ND, 20% ± 8% for IDO-/- AD (Figure 19). The average percentage of II in IDO+/+ mice 
increased non-significantly 5-fold between ND and AD (p=ns) (Figure 19a). A 
significant 79-fold increase in II percentage was found when the IDO-/- AD group was 
compared to the IDO-/- ND group (p=0.0007) (Figure 19b). The average II percentage of 
the IDO-/- AD group was 16-fold higher than the IDO+/+ AD group, a nonsignificant 








Histopathological characteristics of kidney tissues from mice with and without CKD 
(through AD model) stained with H&E and Trichrome were assessed by a blinded 
pathologist. IF and TA were scored from 1-4, then added to glean IFTA (2-8). Percentages 
(0-100%) of GS and II were also established for each sample. The average IFTA score and 
percentage of II in IDO-/- mice increased with AD (p<0.05 and p<0.001), and all other 
comparisons were found to be non-significantly different. IF = interstitial fibrosis, TA = 
tubular atrophy, IFTA = interstitial fibrosis and tubular atrophy, GS = glomerulosclerosis, 
II = immune infiltration, CKD = chronic kidney disease, H&E = hematoxylin and eosin, 






Figure 17: The Effect of Adenine-Supplemented Diet and Genotype on Interstitial 
Fibrosis and Tubular Atrophy Score 
 
A) IFTA scores in IDO+/+ ND mice are not significantly different from those in IDO+/+ ND 
mice (p=ns). B) IFTA scores in IDO-/- AD are significantly higher than in IDO-/- ND mice 
(p<0.05). C) There is no significant observed difference between the IFTA scores of AD 
mice between the IDO+/+ and IDO-/- genotype groups (p=ns). IFTA = interstitial fibrosis 





Figure 18: The Effect of Adenine-Supplemented Diet and Genotype on 
Glomerulosclerosis 
 
A) Average GS percentage in IDO+/+ ND mice is not significantly different from that in 
IDO+/+ ND mice (p=ns). B) Average GS percentage in IDO-/- ND mice is not significantly 
different from that in IDO-/- AD mice (p=ns). C) There is no significant observed difference 
between the average GS percentage in AD mice between the IDO+/+ and IDO-/- genotype 







Figure 19: The Effect of Adenine-Supplemented Diet and Genotype on Immune 
Infiltration 
 
A) Average II percentage in IDO+/+ ND mice is not significantly different from that in 
IDO+/+ ND mice (p=ns). B) Average II percentage in IDO-/- ND mice is not significantly 
different from that in IDO-/- AD mice (p=ns). C) There is no significant observed difference 
between the average II percentage in AD mice between the IDO+/+ and IDO-/- genotype 






Titration of Protein Concentration to Detect IDO in the Kidney 
In order to examine if IDO expression is upregulated in the kidneys in a mouse 
model of CKD, the collected kidney tissues of IDO+/+ and IDO-/- mice receiving a ND 
and a 0.2% AD were immunoblotted to determine IDO protein concentration. First, the 
optimal concentration of tissue lysate (in µg) necessary to detect IDO was determined by 
titrating IDO+/+ kidney tissues from ND mice, in increasing amounts from 20-80µg of 
protein per well (Figure 20). Spleen, a tissue enriched with immune cells where IDO is 
known to be expressed, served as positive control. The optimal concentration was 
determined visually to be >40µg of protein for detectable signal in both the spleen and 
kidney (Figure 20).  
Next, one sample from each group was selected and immunoblotted with these 






Figure 20: Titration of Protein Concentration to Detect Indoleamine 2,3-
Dioxygenase 1 Expression in Mouse Spleen and Kidney Tissues 
 
The concentration of protein was titrated in both spleen (positive control) and kidney 
samples and immunoblotted in increasing amounts from 20-80µg of protein per well. The 
immunoblot was probed for IDO expression, with GAPDH as a control, and the band 
intensity was visually assessed for strongest signal. It was determined that concentrations 
of >40µg were optimal for strong signal. IDO = indoleamine 2,3-dioxygenase 1, kDA = 






Figure 21: Pilot Immunoblot of Indoleamine 2,3-Dioxygenase 1 Expression in IDO+/+ 
and IDO-/- Mouse Kidneys 
 
A pilot immunoblot was run with one kidney sample from each of the four groups 
(IDO+/+ ND, IDO+/+ AD, IDO-/- ND, IDO-/- AD), with 60ug of protein loaded, to compare 
band intensities when probed with IDO (or GAPDH for control). Though the positive 
control did not show a band in this pilot experiment, bands were seen for the other 
samples and all control GAPDH bands were seen. IDO = indoleamine 2,3-dioxygenase 1, 
GAPDH = glyceraldehyde-3-phosphate dehydrogenase, ND = normal diet, AD = 0.2% 




Detection of IDO in the Kidneys of Mouse Model of CKD 
Following the titration of kidney lysate to determine the optimal concentration 
needed to detect IDO protein in IDO+/+ and IDO-/- mice on ND and AD, all samples were 
immunoblotted to determine if IDO expression is increased in the kidneys in the CKD 
mouse model (Figures 22 and 23).  
IDO protein was examined in the kidney samples from IDO+/+ ND mice (n=5, 
Figure 22a) and IDO+/+ AD mice (n=4, Figure 22b). GAPDH served as the loading 
control for all samples. Endogenous IDO protein was undetectable in IDO+/+ ND mice 
(Figure 22a), whereas IDO protein was increased in kidney lysates of IDO+/+ AD mice 
(Figure 22b). IDO signal intensity was 370-fold higher in IDO+/+ AD compared to ND 
(Figure 22c). The average signal intensity for IDO+/+ ND was 119.86 ± 268.01 compared 
to the average signal intensity on AD of 44479.35 ± 5985.96, a significant increase 
(p=0.0007) (Figure 22c).  
IDO protein was also examined in the kidney samples from IDO-/- ND (n=4, 
Figure 23a) and IDO-/- AD (n=4, Figure 23b) mice with GAPDH as the loading control. 
In these samples, endogenous IDO expression was lower in IDO-/- ND mice (Figure 23a) 
than IDO-/- AD mice (Figure 23b). The IDO signal intensity increased 9.5-fold between 
IDO-/- ND and AD (Figure 23c). The average signal intensity for IDO-/- ND was 1175.66 
± 1192.94, compared to the average signal intensity of IDO-/- AD of 12310.34 ± 4699.96, 






Figure 22: Adenine-Induced Model of Chronic Kidney Disease Induces Indoleamine 
2,3-Dioxygenase 1 Protein Expression in IDO+/+ Mouse Kidneys 
 
(A, B) Full immunoblots were run with tissues from each sample mouse from both the 
IDO+/+ ND and IDO+/+ AD groups. The band intensities were quantified in ImageJ and 
compared via ANOVA. C) IDO expression was significantly increased in the AD group 
compared to the ND mice (p<0.001). IDO = indoleamine 2,3-dioxygenase 1, GAPDH = 
glyceraldehyde-3-phosphate dehydrogenase, ND = normal diet, AD = 0.2% adenine-





Figure 23: Immunoblot of Indoleamine 2,3-Dioxygenase 1 Expression in IDO-/- 
Normal Diet and Adenine-Supplemented Diet Mouse Kidneys 
 
(A, B) Full immunoblots were run with tissues from each sample mouse from both the 
IDO-/- ND and IDO-/- AD groups. The band intensities were quantified in ImageJ and 
compared via ANOVA. C) IDO expression was significantly increased in the AD group 
compared to the ND mice (p<0.05). IDO = indoleamine 2,3-dioxygenase 1, GAPDH = 
glyceraldehyde-3-phosphate dehydrogenase, ND = normal diet, AD = 0.2% adenine-
supplemented diet, + ctrl = positive control (spleen), kDA = kilodaltons, µg = micrograms 
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Detection of IDO in Kidneys of Mouse Model of Uremic Milieu 
To assess the effects of uremic solutes on IDO expression in mouse kidneys, 
protein samples from mice with and without IS treatment were immunoblotted for IDO 
with GAPDH as a loading control (Figure 24a). The endogenous IDO expression in the 
kidneys of the mice without IS treatment was undetectable, and IDO expression was 
increased in kidneys of mice treated with IS (Figure 24b). IDO signal intensity increased 
58-fold with IS treatment (Figure 24b). The average signal intensity for IDO in the 
control group (-IS) was 53.43 ± 57.60, compared to 3148.39 ± 1526.25 in the IS 





Figure 24: Indoxyl Sulfate Induces Indoleamine 2,3-Dioxygenase 1 Protein 
Expression in the Kidneys in Indoxyl Sulfate-Specific Solute Model Mice 
 
A) An immunoblot was run with tissues from each sample mouse from both the IS-treated 
(+IS) and control (-IS) groups. The band intensities were quantified in ImageJ and 
compared via ANOVA. B) IDO expression was significantly increased in the AD group 
compared to the ND mice (p<0.05). IS = indoxyl sulfate, IDO = indoleamine 2,3-
dioxygenase 1, GAPDH = glyceraldehyde-3-phosphate dehydrogenase, + ctrl = positive 
control (spleen), kDA = kilodaltons, µg = micrograms 
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Assessment of Endothelial Cell Proliferation and Viability 
 Cell proliferation in the presence of IS was measured using a BrdU incorporation 
assay. BrdU is a thymidine analog which is incorporated into dividing cells and can be 
detected via fluorescence using antibodies against BrdU. The amount of fluorescent 
signal of BrdU is therefore analogous to the amount of cellular proliferation. First, the 
BrdU assay kit was tested using nocadazole, a treatment which arrests the cell cycle and 
prevents mitosis. The baseline fluorescence was found to be 0.1 units with no cells, 
BrdU, or nocadazole, which was not significantly different from BrdU alone (Figure 25). 
Cells with BrdU added fluoresced to 0.3 units, a significantly higher fluorescence than 
that of the baseline and BrdU alone (both p<0.05) (Figure 25). Cells with both BrdU and 
nocadazole added showed a significant decrease in fluorescence compared to cells with 
BrdU only (p=0.0286) (Figure 25).  
 Following confirmation of the BrdU kit’s efficacy in detecting altered levels of 
cell proliferation, three treatment trials were run and results were averaged. Cells were 
treated with 50µM IS for 24h, then labeled with BrdU, and fluorescence was measured at 
2, 4, 8, 12, and 16h post-labeling (Figure 26). A non-significant trend toward decreased 
proliferation was observed through decreased fluorescence of BrdU-labeled cells with 
time (p=ns) (Figure 26). 
 The effect of IS on cell viability was measured using an Alamar Blue assay. 
Alamar blue is a resazurin-based colorimetric assay; upon entering a viable cell, resazurin 
will be reduced to resofurin and fluoresce. Cells were treated with increasing 
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concentrations of IS (0.1µM - 100µM) for 24h, then mixed 1:1 with alamar blue and 
fresh media, and fluorescence was measured at 0, 15, 30, 60, 120, and 240 min post-
alamar blue addition (Figure 27). No significant difference was found in cell viability as 
a result of IS treatment, though increasing IS concentrations caused a trend of decreasing 
cell viability with time as measured by alamar blue relative fluorescence (p=ns) (Figure 
27). 
 To assess the relative expression of uremic pathway solute β-catenin in primary 
endothelial cells, a fractionation experiment was run via immunoblot. Cells were treated 
with 100µM IS, fractionated, and probed for β-catenin with tubulin as the cytosolic 
compartment loading control and fibrillarin as the nuclear compartment loading control 
(Figure 28). Expression of β-catenin was seen in both compartments, but treatment with 







Figure 25: Pilot Cell Proliferation Assay  
 
Efficacy of the BrdU kit in detecting altered levels of cellular proliferation was assessed 
by measuring fluorescence of plates with no HUVEC-TERT cells, just BrdU, HUVEC-
TERT cells with BrdU, and HUVEC-TERT cells with BrdU and nocadazole; results are 
shown. Cells with BrdU added fluoresced significantly more than both plates with no cells 
and plates with BrdU only (p<0.05). With the addition of nocadazole, a significant decrease 
in fluorescence compared to cells with BrdU added was observed (p<0.05). BrdU = 
bromodeoxyuridine, HUVEC-TERT = human umbilical vein endothelial cell with 







Figure 26: Human Umbilical Vein Endothelial Cell Proliferation Trends Toward a 
Decrease with Indoxyl Sulfate Treatment 
 
Cell proliferation of HUVEC-TERTs, assessed as relative fluorescence in BrdU assay, 
shows a non-significant trend of decreasing with IS treatment over time (p=ns). IS = 
indoxyl sulfate, BrdU = bromodeoxyuridine, HUVEC-TERT = human umbilical vein 






Figure 27: Human Umbilical Vein Endothelial Cell Viability Trends Toward a 
Decrease with Indoxyl Sulfate Treatment 
 
Cell viability of HUVEC-TERTs, assessed as relative fluorescence in alamar blue assay, 
shows a non-significant trend of decreasing with higher concentration of IS treatment over 
time (p=ns). IS = indoxyl sulfate, HUVEC-TERT = human umbilical vein endothelial cell 






Figure 28: Indoxyl Sulfate Decreases Cytosolic and Nuclear β-Catenin Expression in 
Primary Human Umbilical Vein Endothelial Cells 
 
A) Treatment of primary HUVECs with 100µM IS followed by fractionation shows a 
decrease in β-Catenin expression in both nuclear and cytosolic compartments. Loading 
controls were tubulin for the cytosolic compartment and fibrillarin for the nuclear 
compartment. B) Quantification in ImageJ shows a decrease in band intensity in the 
cytosolic fraction of IS-treated cells (p=ns). C) Quantification in ImageJ also shows a 
decrease in band intensity in the nuclear fraction of IS-treated cells (p=ns). IS = indoxyl 






The current study examined the effect of IDO on the kidneys and brain 
vasculature in the setting of CKD. 
IDO was shown to have no significant effect on the progression over time of 
clinical renal dysfunction, as assessed by BUN, in the setting of CKD compared to 
controls. Consistent with previous studies, the BUN values of AD mice, regardless of 
genotype, showed a significant increase over time, most likely due to an increase in 
uremic solutes in these mice38–42,49. Though the overall magnitude of CKD effect on BUN 
in mice seemed unaffected by presence of IDO, the extent of kidney damage in individual 
mice may differ, leading to the increased variation seen at certain timepoints. The height 
of kidney injury occurred in both IDO+/+ and IDO-/- after receiving the AD for 14d. The 
slight decline in BUN which followed could be due to decreased protein intake from mice 
being too sickly to consume the diet in adequate amounts or as a result of weight loss due 
to the AD mouse model38–40,67. Further studies with more subjects and more frequent 
sampling would be needed to confirm this hypothesis. 
Measures of IF and TA showed high variability within and between all groups 
regardless of genotype or diet, which may account for the lack of significant difference 
between any of the groups for IF or TA individually. The effects of AD on IF, TA, and 
IFTA in IDO-/- mice appear from the data to be more variable than those on IDO+/+ mice. 
Even in those mice receiving ND, IDO-/- mice tended to have more variable scoring in 
TA and IFTA, though interestingly not in IF only measures. The high variability in 
kidney injury in these samples was also seen in the GS and II measures, so much so that 
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no significant difference was appreciated between any of the groups in terms of GS. This 
variability could be due to an issue with the scoring procedure. Future studies should 
include more mice in each group in addition to multiple blinded pathologists assessing 
levels of IF, TA, GS, and II. Additionally, with dietary administration, it is not feasible to 
control the exact amount of AD each mouse ingests. The variability noted could be due to 
differential amounts of AD ingested by the experimental animals. Future studies could 
alter the route of adenine administration in order to standardize the dosage in each 
animal. Previous studies have been successful in creating the CKD phenotype in rats with 
IP injection (dose of 50 or 100 mg/kg) and oral gavage (150 or 200mg/kg) of adenine68,69.  
The significantly higher average IFTA score and II percentage in the IDO-/- AD 
mice indicate more advanced structural kidney damage and augmented inflammatory 
response in IDO-/- AD mice compared to IDO-/- ND mice. The increased IFTA and II are 
likely a result of increased uremic solute concentration and inflammation in the setting of 
CKD. This exacerbation of IFTA and II in CKD in the absence of IDO is consistent with 
the classical immunosuppressive effects of IDO51,53,56. However, any exacerbation of 
CKD phenotype in these mice is dubious considering the high variability in all of the 
pathological measures (IF, TA, IFTA, GS, II), as described above. 
Immunohistochemical characterization showed increased IDO expression in the 
vasculature of all samples, which is consistent with the effects of the AD model on the 
cardiovascular system and may also be due to the well-established increase of uremic 
solutes in the sera in the setting of CKD39,41,42,45,65. IDO expression in kidney tissues of 
IDO+/+ AD mice changed localization from the glomeruli to the tubules with duration of 
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CKD, possibly due to an increase in inflammation with increasing IDO and uremic 
solutes over the time course of the disease. Interestingly, this seems to be opposite the 
pattern of expression of Fas/FasL in IDO+/+ mice, which normally resides in the tubular 
ECs and is found in glomerular, interstitial, and immune cells with injury, as discussed 
previously48,62. It is possible that the decrease in IDO expression in glomeruli allows for 
increased Fas/FasL pathway action in the glomeruli through increased inflammation over 
time, through the loss of immunoregulatory IDO action. This theory would be consistent 
with the idea of renal inflammatory phenotypes leading to increased Fas/FasL-mediated 
apoptosis, but would contradict the observation of increased Fas/FasL-mediated apoptosis 
in the tubular ECs of IDO+/+ mice and cell models with inflammatory insult62,63. 
Additionally, the immunoblot results offer strong evidence that renal IDO is increased in 
CKD by IS. IDO, classically increased in response to inflammatory cytokines, leads to 
increased apoptosis by inducing tubular EC injury via Fas-FasL expression49,59,63. The 
results of this experiment show a potential alternative method of Fas/FasL-mediated 
apoptosis, through induction of IDO by uremic solutes, suggesting a CKD-specific 
pathway rather than one controlled by pro-inflammatory cytokines42,44,48.  
Further experiments with a larger sample of tissue slides from CKD and uremic 
solute-specific models in both IDO+/+ and IDO-/- mice would be needed to assess the 
relationship between IDO and Fas/FasL expression at baseline and different levels of 
CKD severity and to give information on how uremic solutes are involved in apoptotic 
changes. TUNEL assays to quantify apoptosis and co-staining of Fas/FasL and IDO in 
the setting of CKD and uremic solute-specific models would offer answers to many of the 
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questions raised in this study. In line with the results found in the current study, the 
hypothesized TUNEL assay results would show the IDO-/- samples to have less apoptosis 
than the IDO+/+ mice. Though preliminary TUNEL data (not shown) showed no 
difference in apoptosis between IDO-/- AD and IDO+/+ AD mice, this pilot experiment 
only included one tissue slide from a single mouse in each of the two groups. A larger 
TUNEL assay with slides from multiple mice per group would need to be done to find 
any true difference in apoptosis. Additionally, tissues from IS-specific solute model mice 
would be preferable to AD model mice for this TUNEL assay experiment, since the latter 
is known to cause vastly increased inflammation and cytokine infiltration, which can 
induce apoptosis and therefore may confound apoptotic cell counts via TUNEL.  
 IDO expression was found to be significantly higher with AD model-induced 
CKD compared to controls in IDO+/+ mice. This was expected with the increase in 
inflammation from the AD model and IDO’s increase in the setting of renal injury, as 
previously demonstrated in AKI39,41,59. However, the presence of a positive signal for 
IDO in the IDO-/- mice immunoblots casts doubt on the efficacy of the antibody used. 
Since there is high sequence homology between IDO and IDO2, it is possible that the 
antibody detected IDO2 rather than IDO, as intended. To test the specificity of this 
antibody, the antibody can be pre-saturated with an excess of IDO antigen before 
repeating the immunoblotting experiments. If bands were observed with the IDO pre-
saturated antibody, the protein expression being measured is likely to be IDO2. 
Additionally, other antibodies for IDO, raised against different IDO peptides, should be 
screened to determine the optimal antibody to be used for detection of IDO. These tests 
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would need to be completed to verify the specificity of the antibody and therefore the 
results found in this study or in future studies using the same IDO antibody. 
IDO protein expression was significantly increased in IDO+/+ mice treated with 
IS. This suggests that uremic solutes may directly induce increased IDO in the setting of 
CKD, not only through pro-inflammatory cytokines, as is traditionally known51,52,56,57. It 
may therefore be possible to prevent renal deterioration in the setting of CKD through the 
limitation of uremic solute production. Though the mechanism of IDO increase by 
uremic solutes in the kidney is currently unknown, previous studies suggest that IDO is 
regulated through AHR70. This lab has demonstrated previously that thrombosis in CKD 
is due to an increase in uremic solutes, mediated by increased AHR signaling43,46,47. 
Therefore, inhibition of AHR might sever the link between uremic solutes and IDO. 
Inhibition of AHR signaling will likely prevent IDO increase, which would decrease Kyn 
and its metabolites, leading not only to decreased accumulation of uremic solutes but also 
to further attenuation of AHR activation. Inhibition of IDO either indirectly, through 
AHR or uremic solutes, or directly, using a known inhibitor such as 1-MT, as previously 
shown in AKI, may help to prevent its induction of apoptosis in the renal cells59.  
 Cell proliferation and viability both trended toward a decrease with increased 
concentration of IS treatment over time. Though these results were non-significantly 
different, this could be due to the relatively short timeframe of treatment with IS, since 
CKD is a long-term process and pathogenesis takes much more than 24 hours to appear. 
The fractionation experiment showed that IS, a uremic solute, decreased β-catenin 
expression in HUVECs in both the nuclear and cytoplasmic fractions of cell lysates. 
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β-catenin in ECs is structurally necessary for renal development and the establishment of 
tight-junctions and maintenance of BBB integrity and is involved in disease pathogenesis 
via signaling through transcription modulation71,72. Based on the fractionation results, it is 
hypothesized that accumulation of uremic solutes in CKD may lead to a disruption of EC 
junctions and the BBB through a decrease in β-catenin71,73,74. BBB breakdown through 
loss of tight junction integrity leads to increased CNS permeability, resulting in 
encephalitis, cerebral hemorrhage, and the neurocognitive deficits seen in CKD 
patients10,71,75. AHR is involved in regulation of β-catenin, resulting in its ubiquitination 
and degradation and overall decreased expression76,77. If a decrease in β-catenin is 
involved in the neurocognitive effects of CKD, treatment with an AHR inhibitor may 
help reduce these symptoms by attenuating one of the β-catenin degradation pathways.  
Overall, the results of the present study are inconclusive as to the role of IDO in 
the assessed CKD mouse model. The analyses performed showed no significant 
difference or trends in the renal function or kidney damage between IDO+/+ and IDO-/- 
mice. Further experiments, ideally involving a larger sample size, are needed to help 
ascertain the true effects of IDO on the kidneys in the inevitably variable landscape of 
damage done by the AD model of CKD. It would also be beneficial to test IDO levels in 
different models of CKD, in order to gain a more holistic picture of its effects in CKD 
arising from different etiologies. Once the role of IDO in the kidney during CKD is 
established, further study would be needed into the mechanism of its action as well as the 
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